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Temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) is the most common type of 
pharmaco-resistant epilepsy. It is characterised by recurrent focal onset seizure that 
affects the medial part of the temporal lobe, in particular, the hippocampus. Patients with 
TLE-HS suffer from typical aura symptoms, especially epigastric aura, in addition to 
psychological symptoms which include dysmnestic symptoms such as memory 
impairment and fear. As a result of the important role of the serotonergic system in human 
brain physiological and pathological functions and the crucial need to identify a novel 
target to control seizure among this type of patient, some serotonergic excitatory (5-HT2A, 
5-HT3A, 5-HT4 and 5-HT7) and inhibitory (5-HT1A) receptors were selected to study using 
immunohistochemistry in the human TLE-HS hippocampus, in addition to the purinergic 
receptors (P2x7) and the orphan G-protein (GPR61). The results indicate variable degree 
of upregulation of 5-HT3A, 5-HT1A, 5-HT4, GPR61 and P2x7 receptors in the sclerotic 
hippocampi of TLE-HS patients. Subsequent studies focused on the 5-HT3A receptors 
expression; the overexpression of this excitatory receptor was established using 
immunohistochemistry, SDS-PAGE western blot, receptor autoradiography and 
radioligand binding assays that give comparable results. The upregulation of the 
excitatory 5-HT3A receptor in the excitatory neurons of hippocampus may contribute to 
the neuronal hyperexcitability evident among TLE-HS patients. This study proposed 5-
HT3 receptors as a novel target to antagonise to control seizure in TLE-HS patients and 
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1.1. Temporal lobe epilepsy with hippocampal sclerosis 
Temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) is the most common form 
of epilepsy in humans (Engel, 1998). This disease is defined as symptomatic complex 
partial seizures generated from the medial part of the temporal lobe which contains the 
limbic structures (Engle, 1996). The hyperexcitability in this area presents in various 
symptoms such as epigastric aura and fear (Engle, 1996; Henkel et al., 2002; Wieser, 
2004). This disease is characterised by significant histopathological changes that manifest 
in the form of hippocampal sclerosis (HS) (Mathern et al., 1995; Engel, 1996; Engel, 2001; 
Wieser, 2004; Berg, 2008; Thom, 2014; Cendes et al., 2014). In the early stages of TLE-
HS, pharmacological treatment for this condition exhibits a good control of the seizure 
activity in this type of patient; however, surgical intervention expresses a successful 
control to the seizure activity in 70–90% of patients in the advanced stage of the disease 
when it becomes pharmaco-resistant (Engel, 2001; Wieser, 2004). On the other hand, 
20–30% of surgeries failed to control seizures in this disease population (Harroud et al., 
2012, Surges and Elger, 2013). These unsuccessful surgeries could be due to; 
progressing of underline cause of seizure, inaccurate localization or partial resection of 
the epileptic focus, or presence of multiple epileptic foci (Surges and Elger, 2013). Several 
factors have been suggested as the underlying cause of TLE-HS, which include prolonged 
febrile seizure, cortical malformation, cavernous angiomas, dysembryoplastic 
neuroepithelioma (DNET), intracranial infection and brain hypoxia (Wieser, 2004; Diehl 
and Duncan, 2011). 
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1.1.A. Clinical manifestations 
Patients with TLE-HS present with pre-ictal ascending epigastric aura which is the most 
common type of aura affecting TLE-HS patients (Engel, 1996; Engel, 2001; Wieser, 2004; 
Diehl and Duncan, 2011). Additional possible symptoms are autonomic, cephalic, 
gustatory, psychic or perceptual auras (Engel, 2001; Diehl and Duncan, 2011). These 
auras present for several seconds before proceeding to complex partial seizure (Engel, 
2001). When the complex partial seizure stage initiates, patients with TLE-HS begin 
staring, stop moving and have decreased awareness (Engel, 2001; Diehl and Duncan, 
2011). This initial manifestation is followed by ictal oroalimentary automatisms that include 
swallowing, chewing and lip-smacking (Engel, 2001; Diehl and Duncan, 2011). 
Furthermore, patients could suffer from gestural automatisms such as fidgeting, 
undressing, fumbling, walking and running (Diehl and Duncan, 2011), in addition to 
unilateral upper limb automation that can present in the form of dystonic posturing of one 
limb contralateral to the site of the epileptic foci (Engel, 2001). The ictal phase lasts 
typically for 1–2 minutes (Engel, 2001). This is followed by the post-ictal phase which lasts 
for several minutes or hours in which TLE-HS patients express amnesia for the ictal event, 
disorientation, confusion, short-term memory deficit and dysphasia if the seizure affects 
the brain language (dominant) hemisphere (Engel, 2001; Diehl and Duncan, 2011). 
In terms of electroencephalogram (EEG) examination, the inter-ictal EEG exhibits 
epileptiform abnormality presenting as unilateral or bilateral anterior or mid temporal 
spike-wave discharges (Engel, 2001; Diehl and Duncan, 2011). The ictal EEG recording 
of the epileptiform activity expresses alpha and theta rhythmic discharges observed in the 
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beginning or within 30 seconds from the onset of seizure (Risinger et al., 1989; Engel, 
2001; Diehl and Duncan, 2011). In addition to EEG examination, positron emission 
tomography (PET), using fluorodeoxyglucose (FDG) and magnetic resonance imaging 
(MRI), plays an important role in diagnosing TLE-HS, which can help detect hippocampal 
sclerosis and any inter-ictal pathological changes in the temporal metabolism (Engel, 
2001; Diehl and Duncan, 2011). Patients with TLE-HS express inter-ictal hypometabolism 
on FDG-PET examination (Knowlton et al., 1997; Engel, 2001). Furthermore, a reduction 




The hippocampal sclerosis that is associated with this disease was first observed by 
Bouchet and Cazauvieilh when they detect a neuronal loss in hippocampus and 
cerebellum in brain specimens of epileptic patients (Engel, 2001; Scharfman and Pedley, 
2006 and Meencke, 2009). In 1880, Sommer generated a close observation to the 
hippocampus of patients with TLE-HS and link to the clinical manifestations (Engel, 2001, 
and Scharfman and Pedley, 2006). Sommer identified that, the hippocampal sclerosis is 
unilateral and the neuronal cell loss is not uniform and the most affected area is CA1. In 
addition, he hypothesised that hippocampal pathological changes is the cause behind 
hallucination and illusion in his patients under study (Mathern et al, 1995; Engel, 1996; 
Engel, 2001 and, Scharfman and Pedley, 2006). Two decades later Bratz identify that, the 
pathological changes extended over hippocampus to parahyppocampus gyrus and 
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amygdala and he described the CA2 hippocampal subfield “resistant zone” (Mathern et 
al, 1995; Engel, 1996; Engel, 2001 and, Scharfman and Pedley, 2006). Based on his 
observation he hypothesised that hippocampal sclerosis has an important role in 
epileptogenesis (Mathern et al, 1995; Engel, 1996; Engel, 2001 and, Scharfman and 
Pedley, 2006). 
In addition to the neuronal loss in the sclerotic hippocampus, synaptic axonal 
reorganisation of the granular cell axons (mossy fibres) in hippocampal dentate gyrus was 
detected among patients with refractory epilepsy, this phenomenon is known as mossy 
fibre sprouting (Houser et al., 1990). The granular cells’ mossy fibres were collaterally 
innervating the inner molecular layer of dentate gyrus where the proximal granular cell 
dendrites are located (Scharfman and Pedley, 2006). As a result of that, different scientists 
hypothesised that, the new granular cells’ synapses play a major role in epileptogenesis 
in which the mossy fibres generate an excitatory circuit in dentate gyrus (Sutula et al., 
1992 and Nadler, 2003). On the other hand, other scientists hypothesised that, the mossy 
fibres innervate some of the inhibitory interneurons, which could play an important role to 
reduce neuronal hyperexcitability in dentate gyrus (Scharfman and Pedley, 2006).  
Another important feature that can be observed in the dentate gyrus of TLE-HS patients 
is granular cells dispersion (Houser et al., 1990). This dispersion presents in the form of 
a reduction in the number of granular cells in the dentate gyrus (Scharfman and Pedley, 
2006). Different debatable hypothesis has been suggested to described the reasons 
behind this histopathological phenomenon. Lessberher et al., (2005), hypothesised that 
an abnormal migration of juvenile neuronal cells born prior seizure that led granular 
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dispersion. On the other hand, Frotscher et al., (2003), hypothesis that, the seizure activity 
in the hippocampus altered the radial glial scaffold that resulted in abnormal granular cells 
migration.  
In the modern era, the International League Against Epilepsy (ILAE) classified the degree 
of hippocampal sclerosis based on the level of neuronal loss, affected hippocampal 
subfields and gliosis (Thom, 2014, and Cendes, 2014), this classification includes the 
following: 
 
 HS ILAE type I 
This type of HS was described as the most common type of lesion that affect 60 - 80% of 
the disease population (Cendes, et al., 2014). The type I HS characterised by significant 
neuronal loss affect all of the hippocampal field in different degree. Approximately, 80% 
of the neuronal cells is lost from CA1, 30 – 50% pyramidal cell loss from CA2, in addition 
to 30 – 90% neuronal cell loss in CA3 and 40 – 90% neuronal cells loss in CA4. 
Furthermore, the dentate gyrus (DG) display a variable degree (between 50 – 60%) of 
neuronal cell dispersion (figure 1; Blumcke et al., 2013, Cendes et al., 2014) 
 
 HS ILAE type II 
This form of HS mainly affects the CA1 region leading to pyramidal neuronal cell loss by 
approximately 80% (figure 1; Cendes, et al., 2014). The other hippocampal subfields may 
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display some neuronal loss but does not exceed 25% (Cendes, et al., 2014). Moreover, 
gliosis was detected in CA1, however, no significant granular cells dispersion was 
observed in the DG (Blumcke et al., 2013, Cendes et al., 2014). This type of HS 
considered as one of the rare forms of HS that affect 5 – 10% of all of TLE-HS disease 
population (Cendes, et al., 2014). 
 
 HS ILAE type III 
This form of HS affects the granular cells of DG and neuronal cells of CA4 in which the 
neuronal loss is approximately 30% and 40%, respectively (Cendes, et al., 2014). 
However, the other hippocampal subfield only shows mild to moderate neuronal cell loss 
(Blumcke et al., 2013, Cendes et al., 2014). Around 4 – 7% of the TLE-HS patients are 
suffer from type III HS (figure 1; Cendes, et al., 2014). This form of HS was also described 
previously among patients with limbic encephalitis (Cendes, et al., 2014). 
 
 Hippocampal gliosis (no-HS) 
This non-sclerotic form of histopathological changes in hippocampus was observed in 
approximately 20% of TLE patients (figure 1; Blumcke et al., 2013, Cendes et al., 2014). 
This reactive gliosis was suggested to be seizure focus based on the electrophysiology 
evidence and recently considered as a potent epileptogensis trigger (Cendes, et al., 




Figure 1. Histological classification of hippocampal sclerosis among TLE-HS 
according to ILAE.   
HS ILAE type 1, neuronal cell loss in most of hippocampal subfields with 
preserved neurons in CA2. HS ILAE type 2, neuronal cell loss in CA1. HS ILAE 
type 3, neuronal cell loss affect CA4, dentate gyrus and hippocampal pyramidal 
neurons. Astrogliosis, astrogliosis with no sign of neuronal loss. NeuN 
immunoreactivity signals. Scale bar = 1.0 mm. This figure is adapted from 




Even though the association between hippocampal sclerosis and seizure activity in 
temporal lobe epilepsy patients is confirmed, the relationship between them remains 
unclear. Several hypotheses were suggested to explain this relation. These 
hypotheses include the following: 
 
 The three-stage hypothesis: 
In this hypothesis, the developing TLE-HS passes through three stages. The first stage 
contains the initial precipitating event and includes a medical history that may have 
affected the brain during the early stages of childhood (Baram and Shinnar, 2001). 
This medical history includes meningitis, prolonged febrile seizure, encephalitis and 
head injuries (Scharfman and Pedley, 2006). These events are considered important 
in initiating hippocampal sclerosis because they are common, can cause a permanent 
alteration in the brain and also change its excitability (Scharfman and Pedley, 2006). 
This hypothetical stage remains debatable because, based on clinical observation, 
some patients have developed TLE-HS with no history of an initial precipitating event 
(Scharfman and Pedley, 2006). 
The second stage is the latent period, which is the time between the initial precipitating 
event and the development of TLE-HS (Scharfman and Pedley, 2006). According to 
different experimental results generated using animal models, this is the time of the 
epileptogenesis process (Scharfman and Pedley, 2006). Numerous animal model 
studies were conducted to investigate the histo- and patho-physiological changes that 
occur during this period. The results expressed a wide range of abnormalities that 
9 
 
occurred during this time period. As an example of these alterations in the neuronal 
circuit, mossy fibre sprouting was observed in the animals and led to an increase in 
glutamatergic input (Sutula et al., 1989) and changes in the gap junctions between 
neurons (Nemani and Binder, 2005) and deafferentation of GABAergic interneurons 
(Sloviter, 1991). Regarding changes affecting voltage-gated ion channels, different ion 
channels (Na+, K+ and Ca+2 ion channels) expressed abnormality in the distribution 
and cellular density and alterations affecting the channel modulators (Woo et al., 2002; 
Santoro and Baram, 2003) in addition to several other changes. This stage of the 
hypothesis is not completely agreed upon among scientists and clinicians because 
several TLE-HS conditions exhibit different latent period duration lengths even if they 
are exposed to the same initial precipitating event (Salazar et al., 1985). 
The third stage is the chronic period, when the seizures become spontaneous and 
recurrent (Scharfman and Pedley, 2006). This stage potentially starts at the end of 
epileptogenesis; however, the pathophysiological changes may be continuous and 
affect seizure severity and frequency (Scharfman and Pedley, 2006). Several clinical 
studies confirm that TLE is a progressive condition in which neuronal cells loss and 
mossy fibre sprouting are continuously observed during the disease’s progress 
(Mathern et al., 1995; Pitkänen and Sutula, 2002; Sutula, 2004). In addition, a direct 
relationship of both increased memory deficit and psychological comorbidity with the 




 Temporal lobe epilepsy as a genetic disorder: 
Several studies identified a relationship between TLE-HS and some genetic mutation in 
human and animal models. As an example of these studies is that conducted by 
Kasperavičiūtė et al. (2013) on TLE patients with and without hippocampal sclerosis, with 
medical history of febrile seizure during childhood and those had febrile seizure but not 
developed TLE. The results demonstrate a strong relationship between development of 
TLE-HS after a history of childhood febrile seizure and genetic mutation in SCN1A, which 
is the gene encoding brain-expressed Na+ channel subunit and considered as a target for 
some AEDs (Kasperavičiūtė et al., 2013). 
 
 TLE-HS as neurodevelopment disorder: 
Several studies have investigated the involvement of neurodevelopmental abnormalities 
the in pathogenesis of TLE-HS. According to study conducted by Sloviter et al. (2004), 
8% of hippocampi resected from TLE patients expressed developmental abnormalities 
present in form of neuronal cell dysplasia in addition to an increase in CA1 and subiculum 







1.1.D. Disease management 
 Pharmacological management 
The Scottish Intercollegiate Guidelines Network (SIGN, 2015) on the guideline of the 
diagnosis and management of epilepsy in adult, the following treatment strategy is 
recommended to control focal onset seizures: 
Lamotrigine (sodium channel blocker) considered to be the first line treatment of focal 
seizure with better tolerating profile compared to oxycarbazepine and carbamazepine 
(sodium channel blockers; SIGN, 2015). Lamotrigine is also recommended to use as first 
line therapy especially with older patients who suffer from focal seizure due to its 
tolerability profile and levetiracetam is the drug of choice if the patients suffer from 
Alzheimer’ disease in addition to focal epilepsy (SIGN, 2015). Furthermore, lamotrigine is 
also recommended for adulthood and young women in comparison to carbamazepine and 
oxycarbazepine because it has low tendency to induce hepatic enzymes and increase the 
metabolism of combined oral contraceptives (COCs), however, the plasma concentration 
of lamotrigine is significantly decreased due to glucuronidation, which is induced by COCs 
containing ethinyloestradiol and levonorgestrel (SIGN, 2015). Therefore, lamotrigine dose 
adjustment should be considered when it is used with COCs (SIGN, 2015). The effect of 
COCs on plasma level of lamotrigine is decreased when sodium valproate is included to 
the drug regimen to control seizures (SIGN, 2015).  
When seizures fail to be controlled after a trial of two tolerable AEDs (as monotherapy or 
multiple therapy), the seizures are considered as pharmaco-resistant epilepsy (medically 
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intractable epilepsy) (SIGN, 2015). In this case, based on meta-analysis, levetiracetam, 
carbamazepine, oxycarbazepine, eslicarbazepine, perampanel, gabapentine, pregabline, 
lacosamide, topiramate, lamotrigine and zonisamide can be used as an adjunctive therapy 
to the first line treatment (SIGN, 2015). As a result of the risk of withdrawal seizure and 
poor tolerability, barbiturates are not considered to be used except in specialist epilepsy 
clinics (SIGN, 2015). In addition, some other drugs need close monitoring when they are 
used as adjunctive therapy to control pharmaco-resistant focal seizure, due to their sides 
effects (SIGN, 2015). These drugs include retigabine, which has a strong negative impact 
on the skin and retina (SIGN, 2015). Moreover, vigabatrine is associated with a high risk 
of concentric visual field deficits (SIGN, 2015).   
 
 Non-pharmacological management 
Surgical treatment of TLE-HS is the most effective method to control seizures in patients 
with refractory epilepsy (Ramey et al., 2013). Several forms of surgical approaches may 
be considered for resection (Ramey et al., 2013). First, standard anterior temporal 
lobectomy (ATL), where the hippocampus, amygdala and some of anterior temporal 
cortex resected en bloc (Yasargil et al., 1985, Ramey et al., 2013). Second, selective 
amygdalohippocampectomy (SAH), where in addition to hippocampus and amygdala, 
parahippocampus gyrus resected to minimise the resection of neocortex as far as possible 
(Yasargil et al., 1985, Ramey et al., 2013). According to some studies, there are no 
significant differences between these two approaches, however, other studies find that 
ATL is more beneficial in children and adults (Paglioli et al., 2004, Bate et al., 2007). 
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According to Kwan and Brodie (2000), surgical intervention may have a beneficial effect 
if considered soon after medical intractable epilepsy is confirmed in order to decrease the 
risk of disease complications. According to the randomised control clinical trial conducted 
by Engel et al. (2012) early surgical intervention for the recently diagnosed refractory TLE 
patients is associated with reduction in psychological complications. Considering the 
beneficial outcome of surgical treatment, this type of intervention may be associated with 
some complications regardless to the type of surgical approaches that is used. Some of 
these complications include the following; communicating hydrocephalus, depression, jaw 
pain, memory deficits, speech disturbance, postoperative hematoma which can lead to 
hemiparesis, meningitis and other neurological deficits (Ramey et al., 2013). 
 
Given the failure of current AEDs in many patients with TLE-HS, and in order to avoid 
hippocampal resection where possible, there is motivation to discover a novel target to 
control seizure in TLE-HS patients. Due to the importance of serotonergic receptors in 
CNS, several serotonergic receptors were selected to be assessed in this research 
project. These receptors include; 5-HT1A, 5-HT2A, 5-HT3A, 5-HT4 and 5-HT7 receptors. In 
addition to GPR61 and P2x7 receptors were studied due to the potential relevance and 





The monoamine serotonin (5-hydroxytryptamine, 5-HT) is one of the first discovered 
molecules, and it was isolated from serum by Page et al. in 1948 (Rapport et al., 1948). 
However, eight years previously, in 1940, Erspamer had discovered a contractile 
substance that is secreted by gastric mucosa, particularly the enterochromaffine cells, and 
which affects smooth muscles and blood vessels; a substance that was named entramine 
(Erspamer and Asero, 1952). In 1952, it was discovered that these two compounds were 
identical, and it was decided to call it serotonin (Erspamer and Asero, 1952). This 
ubiquitous molecule, which is known to act as a local hormone, a neuromodulator and a 
neurotransmitter, which is found in the CNS, as well as in other peripheral systems 
(Berumen et al., 2012).  
 
1.2.A. Biosynthesis of 5-HT: 
The serotonin present in the brain is synthesised in neuronal cells and represents 1–2% 
of the total amount of serotonin in the body (Feldman, Meyer and Quenzer, 1997). Its 
synthesis begins with the uptake of a dietary amino acid, tryptophan, from the bloodstream 
into the neuronal cells in a process called active uptake (Pytliak et al., 2011). In the 
neuronal cells, tryptophan is hydroxylated at the 5 position by tryptophan hydroxylase-2 
(tryptophan-5’-monooxygenase; a phenotypic marker for 5-HT neurons), present in very 
low concentrations in neuronal cell bodies, to produce an intermediate compound called 
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5-hydroxytryptophan (5-HTP) (Pytliak et al., 2011). This is the rate-limiting step in 5-HT 
synthesis (Pytliak et al., 2011). 
Immediately after synthesising 5-HTP, this intermediate molecule is transferred to the 
neuronal cells terminal where the majority of 5-HT synthesis occurs (Pytliak et al., 2011). 
Consequently, in the nerve terminal, aromatic amino acid decarboxylase acts by 
decarboxylating 5-HTP to form 5-HT, which is then uptaken from the cytoplasm and stored 
with serotonin binding protein (SBP) in the presynaptic vesicle by a vesicular monoamine 
transporter (Tamir and Gershon, 1990). When these neuronal cells are stimulated, 5-HT 
and SBP are released by exocytosis (Tamir et al., 1994). 
 
1.2.B. Regulation of 5-HT concentration in the synaptic cleft 
Three main regulatory mechanisms control the release of 5-HT and regulate its level in 
synapses. The first mechanism consists of autoreceptors, and two types of these 
regulatory receptors are found in neuronal cells; these are 5-HT1A receptors, which are 
present in somatodendrites, and 5-HT1D receptors, which are known as presynaptic 
autoreceptors present in the human brain (Gothert, 1990, Sharp and Hjorth, 1990). The 
5-HT1A soma and dendrites autoreceptors act by hyperpolarising the neuron and inhibiting 
its firing (Gothert, 1990, Sharp and Hjorth, 1990). This mechanism apparently acts by 
increasing K+ ion conductivity in the cellular membrane and also alters the Ca+2 influx via 
voltage-gated Ca+2 channels (Gothert, 1980). 
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The second mechanism is the activation of 5-HT transporter (serotonin transporter; SERT) 
in the presynaptic domain of serotonergic neurons (Graham and Langer, 1992). Different 
hypotheses have been advanced to explain the mechanism of SERT as a carrier-
mediated function. One of these is that suggested by Marcusson and Ross (1990), in 
which Na+ ions bind to the extracellular domain of the SERT to facilitate 5-HT binding on 
its specific binding site, after which Cl- binds to aid in translocation of these ions and 
molecules to the intracellular domain of the neuron (Marcusson and Ross, 1990).  
Following the first translocation, K+ binds to the intracellular domain of the transporter and 
facilitates its outflux to the extracellular fluid (second translocation) (Marcusson and Ross, 
1990).  
The third regulatory mechanism is catabolism via a mitochondrial enzyme called 
monoamineoxydase A and B (Feldman, Meyer and Quenzer, 1997). In the presence of 
flavin adenine dinucleotide, this enzyme converts 5-HT into 5-
Hydroxyindoleacetaldehyde, which is rapidly metabolised to the primary end product of 5-
HT metabolism, 5-Hydroxyindoleacetic acid (5-HIAA), and excreted to the cerebrospinal 
fluid (Hildebrand et al., 1990). This mechanism, and the two previously described, is 
activated in a 5-HT concentration-dependent manner.  
 
1.2.C. Localisation of the serotonergic system in the brain 
In 1964, Dahlström et al. identified nine 5-HT-containing nuclei (B1-B9), described in table 
(1) (Dahlstroem and Fuxe, 1964). A large cluster of these cell groups is located in the 
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dorsal raphe nucleus of the brain; an area that contains approximately 165,000 cells (Tork, 
1990). In addition, 5-HT neurons are also present in the caudal locus, the area postrema 
and the peri-interpeduncular nucleus (Feldman, Meyer and Quenzer, 1997).  
From these brainstem structures, 5-HT neurons are divided into two main systems; the 
caudal and the rostral (Tork, 1990). The caudal system is located in the medulla and the 
pons and contains B1-B4 cell groups, in which the axons of the neurons innervate the 
medulla and spinal cord (Tork, 1990), while the rostral neuronal system consists of B5-B9 
cell groups, which are present in the contralis superior, the raphe medianus and the raphe 
dorsalis (Tork, 1990). This rostral system consists of ascending neuronal projections that 
innervate the basal ganglia, the limbic system [including the hippocampus where they are 
present in high density in CA3 compared to the dentate gyrus and CA1 (Berumen et al., 
2012)] and the diencephalon via the ventral ascending pathway (originating from B6-B8) 
(Nieuwenhuys, 1985, Feldman, Meyer and Quenzer, 1997). 
 The second neuronal projection is the dorsal pathway, originating from B7-B8, the 
neuronal axons of which innervate the superior and inferior colliculi in addition to the 
mesencephalic gray (Nieuwenhuys, 1985, Feldman, Meyer and Quenzer, 1997). 
Moreover, these ascending pathways combine in the medial forebrain bundle to form the 
ascending system (Nieuwenhuys, 1985, Feldman, Meyer and Quenzer, 1997). In terms 
of their presence in the hippocampus, particularly in the dentate gyrus (DG), these 5-HT 
fibres originate from the median raphe nucleus (known as the M system), and from the 
basket axon system in the DG (Mohler et al., 2007). They are characterised by: 1) thick, 
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non-varicose tract fibres; 2) large, round boutons; 3) thin and short branches and 4) 




Table 1. Anatomical localization of serotonin cell groups 
 (adapted from; Feldman, Meyer and Quenzer, 1997): 
5-HT cell groups Anatomical localisation 
B1 
 Raphe pallidus nucleus 
 Caudal ventrolateral medulla 
B2  Raphe obscurus nucleus 
B3 
 Raphe magnus nucleus 
 Rostral ventrolateral medulla 
 Lateral paragigantocellular reticular nucleus 
B4  Raphe obscurus nucleus, dorsolateral pary 
B5  Median raphe nucleus, caudal part 
B6  Dorsal raphe nucleus, caudal part 
B7  Dorsal raphe nucleus principal, rostral part 
B8 
 Median raphe nucleus, rostral main part 
 Caudal linear nucleus 
 Nucleus pontis oralis 
B9 
 Nucleus pontis oralis 








1.2.D. Serotonergic receptors in the hippocampus 
Different 5-HT receptors are expressed in the hippocampus where they are used by 5-HT 
to produce its physiological and pathological effects. In humans, 5-HT receptors primarily 
consist of seven main types with 14 different subtypes (Nichols and Nichols, 2008). These 
receptors are classified into two groups. The first of these is the ligand gated ion channel, 
to which all 5-HT3 receptors belong (Nichols and Nichols, 2008).  The second group is G-
protein-coupled receptors (GPCRs) group, to which all 5-HT receptors belong (Nichols 
and Nichols, 2008). The current project focuses on an assessment of the expression of 
some 5-HT receptors (primarily 5-HT1A – 5-HT2A – 5-HT3A – 5-HT4 – 5-HT7 receptors) in 
the hippocampus of people with temporal lobe epilepsy with hippocampal sclerosis TLE-
HS. 
 
 Ligand-gated ion channel 5-HT receptors: 
o 5-HT3A receptors: 
The 5-HT3A receptor is an ionotropic ligand-gated, cation-selected ion channel receptor 
that is expressed pre- and post-synaptically in the CNS (Van Hooft and Yakel, 2003). 
These pentameric receptors consist of 5-HT3A subunits, in which the 5-HT3A is the 
functional subunit present in the brain (Nichols and Nichols, 2008). This subunit can form 
a pentameric homomeric (5-HT3A receptor) or heteromeric 5-HT3 receptor when 
combined with other 5-HT3 receptor subunits (3B, 3C, 3D and 3E subunits; Niesler et al., 
2008). Activation of these receptors results in rapid calcium influx and depolarisation 
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(Nichols and Nichols, 2008). This mechanism mediates hippocampal neuronal 
hyperexcitability postsynaptically and neurotransmitters release when the presynaptic 5-
HT3 receptors activated (Barnes et al., 2009). 
In terms of expression in the CNS, 5-HT3 receptors are present in the area postrema, 
solitary tract nucleus and spinal trigeminal nerve nucleus (Nichols and Nichols, 2008). 
Furthermore, these receptors are also located in the nucleus accumbens, caudate 
nucleus, amygdala and putamen (Bufton et al., 1993, Nichols and Nichols, 2008). With 
regard to expression in the hippocampus, 5-HT3 has been detected at relatively low levels 
in all areas of the hippocampal formation (Brady et al., 2007, Nichols and Nichols, 2008), 
with a predominant immunoreactivity detected in CA2 and CA3 pyramidal neurons (Brady 
et al., 2007, Berumen et al., 2012). In addition, both pyramidal neurons of CA1 and 
granular cells of dentate gyrus express low immunoreactivity signals (Brady et al., 2007). 
Expression in these areas of the CNS suggests that 5-HT3 receptors might be involved in 
different physiological and pathological conditions, including higher functions of the brain, 
as well as mood (Nichols and Nichols, 2008) (Table 2), in addition to nausea, vomiting 
and depression (Rocha et al., 2007, Charnay and Leger, 2010, Matthys et al., 2011). 
According to Barnes (2011), 5-HT3A receptors are overexpressed in the GABAergic and 
glutamatergic neurons that are present in the hilus and DG in patients with TLE-HS, 
respectively (Sharma et al., 2007). 
Interestingly, some clinical case reports have described an association between the use 
of ondansetron (a relatively selective 5-HT3 receptor antagonist that is used for the 
treatment and prevention of nausea and vomiting), and generalised tonic-clonic seizures 
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in non-epileptic individuals (Sargent et al., 1993, Sharma and Raina, 2001, George et al., 
2008, Singh et al., 2009, Patel et al., 2011). Two case reports describe generalised tonic-
clonic seizures in patient received ondansetron co-administered with medications that 
decrease seizure threshold such as imipramine, methadone and methylergonovine 
(Sargent et al., 1993 and Mason et al., 2007). Furthermore, seizure associated with toxic 
dose of granisetron (7 – 8 tablets, 10 mg) was reported in 1 years old infant (George et 
al., 2008). In this case, patient developed serotonin syndrome in addition to myoclonus 
and encephalopathy (George et al., 2008). According to Singh et al., (2009) this rare side 




 G-protein-coupled receptors: 
o 5-HT1A receptors: 
5-HT1A is coupled to Gi/0 protein in the hippocampus, where this receptor expresses more 
binding affinity for the G0 than the Gi protein (Nichols and Nichols, 2008, Millan et al., 
2008), and is expressed both pre- and post-synaptically (Nichols and Nichols, 2008, Millan 
et al., 2008, Berumen et al., 2012). Activation of 5-HT1A receptors leads to inhibition of the 
protein kinase A (PKA) and adenylyl cyclase (AC) enzymes, and decreases the 
presynaptic production of cyclic AMP (cAMP) (Nichols and Nichols, 2008, Millan et al., 
2008). In addition, this receptor acts on G-protein gated inwardly rectifying the K+ channel 
(GIRK) via postsynaptic stimulation of G0 protein to mediate hyperpolarisation and inhibit 
neuronal firing (Nichols and Nichols, 2008, Hannon and Hoyer, 2008, Berumen et al., 
2012). Furthermore, these serotonergic receptors act through activation of the Gz protein, 
leading to inhibition of phospholipase C and activation of phospholipase A2 (PLA2) (Millan 
et al., 2008, Berumen et al., 2012).  
The pre-synaptic expression of 5-HT1A receptors in the hippocampus regulates the activity 
of the pre-synaptic neurons and balances the synaptic concentration of 5-HT (Berumen 
et al., 2012). The 5-HT1A receptors are expressed post-synaptically in the excitatory 
pyramidal neurons and granule cells of the hippocampus, in addition to having an 
extrasynaptic localisation (Berumen et al., 2012). Moreover, the 5-HT1A receptor is also 
expressed in astrocytes, ependymal, endothelial and glial cells (Berumen et al., 2012). In 
terms of the expression of 5-HT1A in different hippocampal areas, these inhibitory 
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receptors are present in the DG and CA2 (Okuhara and Beck, 1998, Nichols and Nichols, 
2008, Hannon and Hoyer, 2008, Berumen et al., 2012), CA1 (Nichols and Nichols, 2008) 
and CA3 (Burnet et al., 1995, Okuhara and Beck, 1998, Nichols and Nichols, 2008, 
Hannon and Hoyer, 2008). 
A variety of studies have previously been conducted to assess the involvement of 5-HT1A 
receptors in animal models of TLE-HS. For example, Lopez-Meraz (2005) found that the 
use of (±)-8-Hydroxy-2-(dipropylamino)tetralin hydrobromide (8-OH-DPAT, a selective 5-
HT1A/7 receptor agonist) in a kainic acid-induced seizure rat model resulted in an 
decreased incidence of seizure and possibly increased its latency period. In an intra-
hippocampal kainic acid-induced seizure rat model, this 8-OH-DPAT has been shown to 
delay the latency period and decrease the duration and incidence of the seizure (Gariboldi 
et al., 1996). Furthermore, indorenate (a 5-HT1A receptor agonist) produced the same 
effect on the latency period of a kainic acid-induced seizure animal model (Lopez-Meraz 
et al., 2005). Conversely, the use of a 5-HT1A receptor antagonist (WAY 100635) resulted 
in an increase of the seizure duration and incidence, and it increased the number of 
seizures in intra-hippocampal kainic acid and pilocarpine rat models, respectively 
(Gariboldi et al., 1996, Clinckers et al., 2004a, Clinckers et al., 2004b).   
A number of researchers have attempted to understand the involvement of 5-HT1A 
receptors in the pathogenesis of TLE-HS. Merlet and his colleagues (2004) addressed an 
overexpression of 5-HT1A receptors in extra epileptic focus. However, Ito et al (2007) 
found that these receptors are under-regulated in the hippocampus of patients with TLE 
using PET. With regard to the extra hippocampal areas, these serotonergic receptors 
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showed an under-regulation in the amygdala and neocortex in TLE-HS patients that was 
similar to that observed in people with major depressive disorder (Drevets et al., 2000), 
which might explain the comorbidity of TLE-HS and depression in this type of patient.  
   
o 5-HT2A receptors: 
The 5-HT2A receptor is another 5-HT receptor coupled to G-protein, particularly Gq/11 
(Nichols and Nichols, 2008, Millan et al., 2008 Pytliak et al., 2011). In the hippocampus, 
this coupling leads to hydrolysis of phosphoinositides from the cell membrane and forms 
the second messengers, diacylglycerol and inositol phosphate (Nichols and Nichols, 
2008), which activate PLA2 and arachidonic acid in the hippocampus, leading to an 
increase of Ca+2 concentration in the cytoplasm  (Millan et al., 2008, Pytliak et al., 2011). 
Furthermore, in the cerebral cortex, 5-HT2A receptors activate protein kinase C (PKC), 
which also elevates intracellular Ca+2 concentration (Millan et al., 2008, Pytliak et al., 
2011).   
With regard to the expression of 5-HT2A receptors in the human brain, they are distributed 
post-synaptically in CA1 and CA3 hippocampal pyramidal cells in the granular layer of the 
DG and astrocytes (Berumen et al., 2012). This expression in hippocampal fields is lower 
than that found in the parahippocampal gyrus and cerebral cortex (Burnet et al., 1995). 
The expression of 5-HT2A receptors in these particular brain regions suggests that these 
receptors might play an important role in memory and learning (Charnay and Leger, 2010) 
(Table 2), which deteriorate in people with TLE-HS.  
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With regard to experimental studies of 5-HT2A receptors in a TLE-HS animal model, 
ritanserin (a nonselective 5-HT2 receptor antagonist) does not exert any effects in a kainic 
acid-induced seizure rat model (Velisek et al., 1994). However, there are currently no 
available data concerning the involvement of 5-HT2A receptors in the pathogenesis of TLE-
HS in humans.   
 
o 5-HT4 receptors: 
5-HT4 receptors act by coupling to Gs protein, leading to activation of AC and PKA (Nichols 
and Nichols, 2008, Millan et al., 2008 Pytliak et al., 2011), and stimulation of cAMP 
(Nichols and Nichols, 2008). In CA1 pyramidal cells in the hippocampus, activation of 5-
HT4 receptors inhibits Ca+2 activated K+ channels, which are responsible for slow after-
hyperpolarisation (Nichols and Nichols, 2008). Moreover, activation of these receptors in 
CA1 is involved in long-term depression, but not long-term potentiation (Nichols and 
Nichols, 2008). In addition, 5-HT4 receptors counteract the activity of 5-HT1A receptors, 
whereby stimulation of 5-HT4 receptors produces rapid direct stimulation of serotonergic 
neurons and increases their firing, leading to desensitisation of 5-HT1A receptors 
(Berumen et al., 2012). Regarding the expression of 5-HT4 receptors in the human brain, 
in situ hybridisation has identified their mRNA in the hippocampus (Berumen et al., 2012). 
Furthermore, this receptor type is present in the substantia nigra, the basal ganglia and 
the cerebral cortex (Bonaventure et al., 2000, Nichols and Nichols, 2008). According to 
Waeber et al. (1993) the radioligand binding activity in the hippocampus, colliculus and 
neocortex is lower than that found in the striatum and substantia nigra. With regard to 
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distribution in the hippocampus, Bonaventure et al. (2000) asserted that 5-HT4 receptors 
are found in all of the hippocampal formations with the exception of the hilus. The 
expression of 5-HT4 receptors in these hippocampal areas means that they play an 
important role in cognition (Mohler et al., 2007). In addition, they might be indirectly 
involved in memory formation by mediating a regulatory effect on acetylcholine release 
from cholinergic neurons in the hippocampus (Fink and Gothert, 2007, Pytliak et al., 2011, 
Berumen et al., 2012) (Table 2). Of involvement in TLE-HS, Rocha (2007) and her 
colleagues observed that there is an increase in the binding affinity of 5-HT4 receptors in 
layers V and VI of the neocortex of people with TLE-HS. This elevation in receptor binding 
activity has a direct relationship with the duration of the disease (Rocha et al., 2007). 
However, low binding affinity was detected in layers III and IV of the neocortex in patients 
with a long duration of seizures or who had been on AEDs for an extended period of time 
(Rocha et al., 2007).    
 
o 5-HT7 receptors: 
In a manner similar to 5-HT4 receptors, metabotropic 5-HT7 receptors act by activating Gs 
protein, leading to activation of AC and PKA in the hippocampus (Millan et al., 2008, 
Berumen et al., 2012). This receptor type also activates G12 protein in the hippocampus, 
leading to the activation of Rho and cell division control protein 42 (Cdc42) (Millan et al., 
2008). With regard to the level of expression of 5-HT7 receptors, a variety of studies have 
been conducted on the human CNS, and the results have shown that this receptor is 
present in the cortex, thalamus, hippocampus (Jasper et al., 1997, Belenky and Pickard, 
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2001, Terron et al., 2001, Nichols and Nichols, 2008), hypothalamus (Nichols and Nichols, 
2008), suprachiasmatic nucleus, amygdala and trigeminal ganglia (Jasper et al., 1997, 
Terron et al., 2001). The immunoreactivity of 5-HT7 in the hippocampus has been detected 
in CA3, CA2 and CA1 pyramidal cell bodies, but not in interneurons (Berumen et al., 
2012). This distribution in the human brain suggests the involvement of this receptor type 
in different physiological functions, such as mood control, neuroendocrine vegetative 
behaviour and learning (Berumen et al., 2012) (Table 2), as well as memory, circadian 
rhythms and thermal regulation (Matthys et al., 2011).  
With regard to the involvement of these receptors in the neurotransmitter network, they 
regulate glutamate and γ-aminobutyric acid (GABA) transmission in the hippocampus 
(Berumen et al., 2012, Rocha, 2013). Post-synaptic 5-HT7 receptors facilitate α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor transmission between the 
pyramidal neurons of CA3 and CA1 (Berumen et al., 2012, Rocha, 2013, Andreeta et al., 
2016), in addition to blocking the inhibitory effect of GABA (Rocha et al., 2007). 
In the context of experimental studies that have been conducted to understand the role of 
5-HT7 receptors in animal models of TLE-HS, Yang (2012) found that the use of AS19 (a 
5-HT7 agonist) increased spike-wave discharge and the frequency of the spontaneous 
seizure, in a pilocarpine-induced seizure rat model. In contrast, the use of SB269970 (a 
5-HT7 antagonist) decreased these effects (Yang et al., 2012). 
Regarding involvement in pathological conditions, a variety of studies have shown that 5-
HT7 receptor expression is altered in pain, schizophrenia, epilepsy and depression 
(Matthys et al., 2011). Moreover, Yang and his colleagues (2012) studied expression of 
29 
 
5-HT7 receptors in the neocortex of TLE-HS patients and found an overexpression of this 
receptor type among this group of patients. Furthermore, the binding affinity of 5-HT7 
receptors was reduced in TLE-HS patients on long-term AEDs (Rocha et al., 2007).
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Table 2. Physiological and pathological functions of 5-HT receptors in human brain  
 (Rocha et al. 2007; Charnay et al., 2010; Barnes, 2011 and Matthys et al., 2011).
Receptor Physiological involvement Pathological involvement 
5-HT1A 
Regulate 5-HT activity, 
learning, memory, cognition, 





5-HT2A Respiratory control and mood. Schizophrenia and anxiety. 
5-HT3 Mood and vomiting reflex. 
Epilepsy, nausea depression, 
and anxiety. 
5-HT4 
Cognition, reward and 
feeding. 
Epilepsy, anorexia, addiction and 
Alzheimer. 
5-HT7 
Cognition, mood and 
circadian rhythm. 
Schizophrenia, depression, 
anxiety, and epilepsy. 
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1.3. The orphan G-protein, GPR61 
GPCRs are considered a superfamily that acts as a transducer for the extracellular 
messengers and produce cellular response through a wide range of signalling pathways 
(Lee et al., 2001, Cikos et al., 2001, Takeda et al., 2003, Toyooka et al., 2009, Nambu et 
al., 2011, Martin et al., 2015, Hossain et al., 2016). Some of these GPCRs are known as 
orphan G-proteins which are proteins whose endogenous ligands are undiscovered 
(Martin et al., 2015). GPR61 is one of these orphan G-proteins that was first identified in 
the human brain by Lee et al. (2001) and cloned by Cikos et al. (2001). Similar to other 
G-proteins, GPR61 consists of seven transmembrane domains with approximately 28–
31% homology to biogenic amines such as histaminergic, dopaminergic, serotonergic (in 
particular, 5-HT6 receptors) and adrenergic GPCRs (Lee et al., 2001, Cikos et al., 2001).  
Regarding the expression of GPR61 in human brain tissue, GPR61 mRNA is highly 
expressed in the hippocampus, occipital pole, amygdala, cerebral cortex, frontal lobe, 
temporal lobe (Cikos et al., 2001) and thalamus (Lee et al., 2001). This GPCRs mRNA is 
expressed at low levels in the putamen and caudate (Lee et al., 2001, Cikos et al., 2001). 
Expression of GPR61 in these areas may indicate that this protein may be involved in 
higher brain functions such as learning, memory and cognition (Cikos et al., 2001).  
According to Takeda et al. (2003), GPR61 is coupled to Gs-proteins. In addition, it 
expresses a constitutive activity which is maintained by the GPR61 N-terminal that acts 
as a tether for the intramolecular ligand (Toyooka et al., 2009). Regarding the intracellular 
signalling of GPR61, plasmalogens (Pls) (which are cell membrane structure components 
in the CNS) act on GPR61 and other GPCRs (GPR1, GPR19, GPR21, GPR27) to activate 
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heterodimer formation among these GPCRs (Hossain et al., 2016). The formation of 
heterodimers lead to the phosphorylation of extracellular signal-regulated kinases (ERK) 
and protein kinase B (PKB or AKT) in neuronal cells (Hossain et al., 2016). This effect is 
evoked in GPR61, GPR1, GPR19, GPR21, GPR27 knockout cells (Hossain et al., 2016). 
In 2003, Takeda et al. suggested a surrogate ligand for GPR61, 5-(nonyloxy)tryptamine 
(a potent 5-HT1D receptor agonist with moderate affinity to 5-HT1A receptors), which 
exhibits a low affinity GPR61 inverse agonist.  
In terms of the biological role of GPR61, a physiological study conducted by Nambu et al. 
(2011), using GPR61 knockout mice, indicated involvement in regulating feeding 
behaviour. This finding is suggested to be a result of the hyperphagia and obesity 
observed among GPR61 knockout mice, in addition to the normal expression of GPR61 
in brain regions that regulate food intake (Nambu et al., 2011). These areas include the 
hippocampus (regulates ingestion learning and memory), nucleus accumbens (regulates 
feeding behaviour motivation) and nucleus tractus solitarius (which is the response to 
feeding sensory input from the viscera) (Nambu et al., 2011). To our knowledge, no data 
are available about the protein expression of GPR61 in the human normal hippocampus 
or in the sclerotic hippocampus of TLE-HS patients. Therefore, it was opportunistic to 
study GPR61 in normal and TLE-HS diseased hippocampi.
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1.4. Purinergic channel, P2x7 
Purinergic P2x7 receptors are a subclass of the P2x non-selective ion channel family, 
consisting of two transmembrane domains with long extracellular loops consisting of 
multiple cysteine and glycosylation moieties with short intracellular N-terminals and 
long C-terminals in comparison to other types of P2x families (Sperlágh et al., 2006, 
Skaper et al., 2010, Engel et al., 2012b, Sperlágh and Illes, 2014). This receptor has 
a relatively low affinity to adenosine triphosphate (ATP) being activated by 
approximately millimolar concentrations of ATP (pathological concentrations of ATP) 
compared to other P2x receptor families which require low micromolar ATP to be 
activated (Sperlágh et al., 2006, Skaper et al., 2010, Engel et al., 2012b, Sperlágh and 
Illes, 2014). P2x7 receptors exhibit  a low tendency for desensitisation (Engel et al., 
2012b). Activating P2x7 receptors results in increased Ca+2, Na+ influx and K+ outflux; 
however, prolonged activation of this receptor facilitates the opening of non-selective 
pores that allow large molecules (600–900 Da) to traverse the membrane (Skaper et 
al., 2010, Engel et al., 2012b). This later phenomenon is not well understood but there 
are several hypotheses to explain the formation of these pores. One is that the 
structural modification of the channel leads to the dilatation of the P2x7 ion channel 
itself, similar to that observed with P2x2 and P2x4 (Chaumont and Khakh, 2008). 
According to Sun et al. (2013), both the C-terminal and the second transmembrane 
domain are involved in the P2x7 ion channel dilatation. The second possible hypothesis 
is the involvement of the hemichannel protein, panexin-1 (Panx1), which acts as a pore 
formation protein which is activated as downstream signalling of the stimulated P2x7 
receptors (Skaper et al., 2010). This hypothesis is controversial. According to some 
scientists, Panx1 is essential for the pore formation and can be blocked using 
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colchicine (Marques-da-Silva et al., 2011, Suadicani et al., 2012). On the other hand, 
other groups of scientists have suggested that the involvement of Panx1 is not 
essential for pore formation because different P2x7 splice variants express different 
pore formation characters (Xu et al., 2012, Schwarz et al., 2012).  
In terms of activating signalling pathways, activating P2x7 receptors can drive 
activation of mitogen-activated protein kinases (MAPK), caspase-1, interleukin 1β (IL-
1β), phospholipase A2, phospholipase D, extracellular signal regulated kinase 
(ERK1/2), tumour necrotic factor α (TNFα) and nuclear factor-ƙB (Labrousse et al., 
2009, Krueger et al., 2010, Csölle and Sperlagh, 2010, Girotti et al., 2013). Moreover, 
this receptor can activate the cAMP response element-binding protein (CREB), c-Jun 
terminal kinases 1/2 (JNKs1/2) and microglia, and it can control its proliferation, in 
addition to inhibiting glycogen synthase kinase-3 (Labrousse et al., 2009, Csölle and 
Sperlagh, 2010, Barberà-Cremades et al., 2012). 
In the CNS, P2x7 receptors play an important role in controlling glutamate, GABA and 
other neurotransmitters in the synaptic cleft (Sperlágh et al., 2002). P2x7 acts as an 
autostimulatory receptor in the hippocampus by activating the release of ATP (Heinrich 
et al., 2012). The mechanism of this phenomenon is not fully understood; the ATP 
could be released by exocytosis, through Panx1 and/or connexin hemichannel proteins 
(Gutiérrez-Martín et al., 2011, Bennett et al., 2012, Heinrich et al., 2012).  
Regarding the normal expression of P2x7 receptors, Rassendren et al. (1997) and 
Cheewatrakoolpong et al. (2005) found that, using northern blot and qPCR, the mRNA 
of this receptor is present in human brain tissue. Furthermore, the immunoreactivity of 
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this excitatory receptor was detected in microglia using immunohistochemistry 
(Yiangou et al., 2006). 
As to the involvement of P2x7 receptors in the pathogenesis of TLE-HS, the 
immunoreactivity of P2x7 receptors is significantly increased in the neurons, astrocytes 
and microglia of animal models of status epilepticus induced by pilocarpine and kainate 
(Kim et al., 2009, Dona et al., 2009). Moreover, stimulating P2x7 receptors has been 
associated with an increase in the epileptic activity in the kainate animal model of 
status epilepticus (Engel et al., 2012a, Jimenez-Pacheco et al., 2013). However, 
stimulating P2x7 receptors in the same animal model increased post-ictal astrogliosis 
and leukocyte infiltration (Kim et al., 2010, Kim et al., 2013). On the other hand, 
antagonizing this receptor produces a neuroprotective effect against the negative 
impact of epilepsy by inhibiting IL-1β release and suppressing microglia activation 
(Engel et al., 2012a, Jimenez-Pacheco et al., 2013). Interestingly, antagonizing P2x7 
receptors with A-438079, a competitive P2x7 receptor antagonist, facilitates seizure 
activity in pilocarpine mouse models of status epilepticus (Kim and Kang, 2011). This 
effect results from suppressing the inhibitory effect of activated P2x7 on neuronal 
muscarinic receptors (Kim and Kang, 2011). Regarding the expression of P2x7 in brain 
samples of patients with TLE-HS, this purinergic receptor expresses an upregulation 
in the neocortex (Jimenez-Pacheco et al., 2013) and in the hippocampus of TLE-HS 
patients (Fernandes et al., 2009). According to Barros‐Barbosa et al. (2015), activating 
P2x7 receptors in the neocortex nerve terminals of TLE-HS patients is associated with 
further downregulation of GABA and glutamate uptake in comparison to post-mortem 
control samples. This finding indicates that the excessive release of ATP during 
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seizure suppresses GABA and glutamate uptake into nerve terminals (Barros‐Barbosa 






Previous research on the expression of 5-HT3A, 5-HT2A, 5-HT4, 5-HT7 and P2x7 
receptors in the human hippocampus demonstrates that these excitatory receptors are 
present in excitatory pyramidal and granular neurons, which exhibit neuronal 
hyperexcitability in TLE-HS patients. This led to the hypothesis that these excitatory 
receptors are upregulated in the excitatory neurons of the hippocampus and are 
involved in neuronal hyperexcitability and seizure generation. Antagonising these 
receptors introduce a better control for seizure activity in patients with TLE-HS and 
improve their quality of life.  
Similar to the expression of the previous excitatory receptors, numerus studies on the 
expression of inhibitory 5-HT1A receptors in the human hippocampus show the 
localization of this inhibitory receptors on the excitatory pyramidal and granular 
neurons and it is control their neuronal firing. In addition, the binding activity of 5-HT1A 
receptors is decrease in hippocampus of patients with TLE-HS. These studies led to 
the following hypothesis, the expression of inhibitory 5-HT1A receptors is decreased in 
the hippocampus of TLE-HS patients and is indirectly involved in neuronal 





The aim of this study is to investigate the pathophysiological alteration of various 
relevant serotonergic receptors, P2x7 receptors and GPR61 protein associated with 
the most common type of epilepsy among adults (TLE-HS). These changes may play 
a role in pathogenesis of TLE-HS. This study may help in understanding the role of the 
targets receptors and protein in the mechanism underline TLE-HS. In addition, this 
may facilitate identification of novel targets and developed new compounds to control 
seizures in TLE-HS patients with less tendency to developed adverse effects. This may 
















2. Materials and methodology 
2.1. Human brain samples 
The TLE-HS surgically resected hippocampal samples and some post-mortem control 
samples were obtained from Queen Elizabeth Hospital (Birmingham, UK) after the 
patients gave their informed consent which was ethically approved by the Human 
Biomaterial Resource Centre (HBRC, University of Birmingham, Birmingham, UK). 
These samples were obtained in forms of formalin-fixed paraffin-embedded (FFPE) 
sections or fresh and snap-frozen blocks (Table 3). In addition, other TLE-HS snap-
frozen hippocampi were obtained from Queen Square Brain Bank for Neurological 
Disorders (University College of London, London, UK) (Table 3). Age-matched post-
mortem control hippocampi were obtained from donors with no history of neurological 
and psychological disorders that were ethically approved by Edinburgh Brain Bank 
(University of Edinburgh, Edinburgh, UK). These samples were used in forms of FFPE 
and snap-frozen blocks. All of these institutions were accredited by the UK Human 




2.2. Mimicking post-mortem delay: 
The surgically resected TLE-HS hippocampus was transferred from theatre to our lab 
in ice could oxygenated sucrose solution (NaHCO3 25, CaCl2 1, KCl 3, MgCl2 10, D-
Glucose 10, sucrose 250, mM) within 30 min post resection. To mimic post-mortem 
delay, an artificial post-mortem delay protocol conducted using artificial cerebrospinal 
fluid (aCSF; NaHCO3 25, CaCl2 2, KCl 4, MgCl2 2, D-Glucose 10, NaCl 125, mM). In 
this protocol, the sample incubated in aCSF for 18 hour at room temperature followed 
by 48 hour at 4⁰C then for 4 hours at room temperature before being snap frozen it for 




Table 3. Demographical information of hippocampus donors. 









TLE1 46 Male --- --- 
TLE2 33 Female --- --- 
TLE3 24 Female --- --- 
TLE4 30 Female --- --- 
TLE5 30 Female --- --- 
TLE6 37 Male --- --- 
TLE7 40 Male --- --- 
TLE8 49 Male --- --- 
PMC1 63 Male --- 41 
PMC2 47 Male --- 42 
PMC3 46 Female --- 49 
PMC4 63 Male --- 42 
PMC5 39 Female --- 43 
PMC6 38 Male --- 36 
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PMC7 53 Male --- 53 
PMC8 45 Female --- 40 
PMD1 36 Male --- 70 
PMD2 52 Male --- 70 






TLE1 38 Female 
Betahistine                      
Dexamethasone                      
Lamotrigine                                 
Movicol 
Paracetamol                                        
Senna                                              
Zopiclone 
---
TLE2 18 Male Topiramate Zonisamide --- 
TLE3 45 Female 
Chlorphenamine                                                        
Codeine 
Phosphate                     
Lamotrigine                                      
Lansoprazole 
Oxcarbazepine                                   
Paracetamol                                           
Pregabalin                                                         
Senna 
--- 
TLE4 31 Male 
Metoclopramide                                
Carbamazepine                                         
Codeine 
Phosphate                        
Levetiracetam 
Paracetamol                                         
Sodium Valproate                                  
Zopiclone 
---
Table 3. Continue  
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TLE5 42 Male 
Chlorphenamine                                   
Citalopram                                   
Dexamethasone                                  
Lansoprazole 
Levetiracetam                                       
Simvastatin                                                    
Sodium Valproate 
---
TLE6 24 Female 
Lamotrigine 
Codeine 
Phosphate                                 
Lactulose 
Senna 
Lansoprazole                                   
Levetiracetam                                    
Paracetamol 
--- 
TLE7 33 Female Oxcarbazepine Pregabaline --- 




TLE9 45 Male Private Patient --- 




TLE11 30 Female 








PMC1 35 Female --- 44 
PMC2 20 Male --- 36 











Table 4. Demographic information of old samples used in receptors expression 
assays. 
 
Assay Type of sample (n) 
Range of age 
(year) 




TLE-HS (5) 34 – 48 -- 
PMC (7) 55 – 91 13 – 48 
Receptor 
autoradiography 
TLE-HS (9) 16 – 55 -- 
PMC (10) 19 – 73 Up to 21 
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2.3. Immunohistochemistry (IHC) method development 
2.3.A. Optimising antigen retrieval 
In order to determine the optimal method for antigen retrievals that was compatible 
with different primary antibodies, various conditions were tested. The first was Heat 
Induced Epitope Retrieval (HIER), which used warm citric acid (CA), and the second 
was Enzyme-Induced Epitope Retrieval (EIER), where Protienase K (PK) was used at 
37°C. 
The 4 µm thickness formalin-fixed paraffin-embedded (FFPE) slides were dewaxed by 
incubating them in xylene overnight. The following day, they were rehydrated through 
a serial dilution of ethanol (100% [2X], 95%, 70%) and deionised water (dH2O) for 10 
min each at room temperature. Then, the slides that underwent antigen retrieval using 
HIER were incubated in boiling citric acid (10 mM, pH = 6) for 7 or 10 min before being 
cooled under running tap water (Table 5). On the other hand, slides that underwent 
EIER were incubated in 20 µg/ml PK (pH = 8) for different incubation times (5, 10, 20, 
and 30 min) at 37°C, followed by 10 min of incubation at room temperature, then 
washed with dH2O (Table 5). After the antigen retrieval, the slides were incubated in 
0.03% H2O2 for 30 min at room temperature to block the endogenous peroxidase 
activity. After that, the slides were washed with dH2O, then phosphate buffer saline 
(PBS, 130 mM NaCl, 7 mM Na2HPO4, 3 mM NaH2PO4, pH = 7.4) three times for 1 min 
each and incubated in permeabilization buffer (0.3% Triton X-100 in PBS, pH = 7.4) 
for 1 hour at room temperature. One hour later, the slides were incubated in blocking 
buffer containing 10% fetal bovine serum (FBS) and 0.3% Triton X-100 in PBS at room 
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temperature for one more hour, followed by primary antibodies (Table 6) being 
incubated overnight at 4°C. 
The next day, the slides were washed extensively with permeabilization buffer three 
times for 10 min each and then covered with blocking buffer for 5 min at room 
temperature in order to block non-specific binding. As the next step, the slides were 
incubated with suitable biotinylated secondary antibodies (Table 6) for two hours at 
room temperature. After that, the slides were washed with permeabilization buffer and 
covered with Avidin-Biotin complex (ABC, ABCelite, Vector Laboratories, 
Peterborough, UK) for 30 min at room temperature. In order to visualise the target, 
staining with 0.025% diaminobenzidine (DAB, Vector Laboratories, Peterborough, UK) 
was used to produce a brown colour for the target. This was accomplished by 
incubating the slides on DAB for 6 min with 45-sec intervals between each of the two 
slides. Next, the slides were washed with permeabilization buffer for 1 min and then 
with dH2O. Finally, the slides were dehydrated through serial dilution of ethanol and 
then cleaned with xylene. One drop of DePex (Sigma Aldrich, St. Louis, Missouri, US) 
was added to stabilise the cover-slip, and after drying the slides were visualised using 
a light microscope. 
In order to confirm that the immunoreactivity signals are resulting from the 
immunological interaction between target epitopes and antibody-detection reagents 
complex prototypes, no primary antibody control hippocampal slides were included in 
the IHC experiments. In this study, the slides were subjected to the IHC staining 
protocol and the primary antibody was replaced with blocking buffer. 
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Table 5. Immunohistochemistry antigen retrieval step conditions: 









Incubation time I 
(min) / temperature 
Incubation time II 
(min) / temperature 
Citric acid / dH2O dH2O / RT 
10mM Citric acid 
pH=6 
10 min / 90°C None 
Citric acid / DPC-treated H2O 
DPC-treated H2O / 
RT 
Proteinase K / dH2O dH2O / RT 
20 µg/ml Proteinase K 
pH=8 
10 – 15 – 20 - 30 min / 
37°C 
10 min / RT 
Proteinase K / DPC-treated 
H2O 




Table 6. Immunohistochemistry and western blots antibodies concentrations: 





Rabbit anti-human 5-HT1A receptors Polyclonal Abcam Ab79230 1:750 -- 
Mouse anti-human 5-HT2A receptors Monoclonal BD PharMingen 556326 1:500 -- 
Rabbit anti-human 5-HT3A receptors Polyclonal Abcam Ab13897 1:600 1:750 
Rabbit anti-human 5-HT4 receptors Polyclonal Abcam Ab60359 1:750 -- 
Rabbit anti-human 5-HT7 receptors Polyclonal Abcam Ab101913 1:750 -- 
Rabbit anti-human HPRT1 protein Polyclonal Abcam Ab10479 -- 1:2500 
Mouse anti-human GFAP protein Monoclonal Chemicon MAB3402 1:500 -- 
Mouse anti-human P2X7 receptors (IgG2a) Monoclonal 
Collaborator from 
University of 
Melbourne    
-- 1:100 -- 






-- 1:6000 -- 
Biotinylated goat Anti-rabbit IgG (H+L) -- Vector laboratories BA-1000 1:500 -- 
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Biotinylated horse Anti-mouse IgG (H+L) -- Vector laboratories BA-2000 1:500 -- 
Biotinylated rabbit Anti-goat IgG (H+L) -- Vector laboratories BA-5000 1:750 -- 
HRP-linked Anti-rabbit IgG (H+L)  -- Santa Cruz SC-2004 -- 1:2000 
 
Table 6. Continue.  
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2.3.B. Optimising IHC staining for use in RNA extraction and qPCR 
Due to the limited amount of samples, and in order to maximise the amount of 
information that could be obtained from these samples, RNA was extracted from IHC-
stained slides. This was done by modifying the staining protocol and replacing dH2O 
with DPC (diethylpyrocarbonate) treated water and using it to prepare buffers and 
solutions in addition to washing the slides (Table 5). 
 
2.3.C. Optimised IHC protocol 
The optimal conditions selected for IHC were based on the previous optimisation; 1) 
use HIER for 7 min for antigen retrieval for all of the sections used to study the 
expression of 5-HT (1A – 3A – 4 – 7) receptors, GFAP, P2X7 receptors and GPR61. 2) Use 
EIER for 20 min at 37⁰C then 10 min at room temperature for the sections used to 
study the expression of 5-HT2A receptors.  
 
2.3.D. Nuclear counterstain for IHC: 
The nuclear counterstain was applied to the no primary control slides in order to avoid 
the overlap between the brown color of immunoreactivity signals and hematoxylin 
purple background that may affect the intensity of immunoreactivity signals. The no 
primary control slides were incubated in xylene to remove the mounting media and 
glass coverslip. The slides, then rehydrated through serial dilution of ethanol (100% 
[2X], 95% and 70%) followed by dH2O for 2 min each. The slides were then incubated 
in hematoxylin (Sigma-Aldrich, St. Louis, Missouri, USA) for 30 sec at room 
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temperature and the excess of the dye removed by dH2O. At the end the slides were 
dehydrated using a gradual concentration of ethanol, then xylene for final clearing and 
visualized under light microscope. 
 
2.3.E. Polymer Biotin-Tyramide ABC (PBTA) IHC staining technique 
This method was conducted as described by Goto et al. (2015). First, the slides were 
deparaffinised and rehydrated. The sections were then placed in boiled citric acid 
(10mM, pH= 6) for antigen retrieval. After that, the sections were blocked with 10% 
FBS in a permeablising buffer for 1 hour, and then they were incubated with different 
concentrations (1:6000, 1:60,000, and 1:100,000) of goat anti-human GPR61 (table 6) 
for 48 hours at 4°C. These slides were then washed with a permeablising buffer and 
covered with a 10% FBS blocking buffer for 5 minutes at room temperature. Next, the 
slides were incubated for 30 minutes with a polymer staining solution (Histofine simple 
stain kit, Nichirei, Tokyo, Japan) at room temperature. The slides were then thoroughly 
washed with PBS and covered for 30 min with 1:50 tyramide signal amplification (TSA) 
biotin system (Perkin Elmer, Boston, MA, US) that had been freshly prepared 
according to the manufacturer’s instructions. The slides were again washed with PBS 
and covered with ABCelite for 30 minutes at room temperature. At the end, similar to 
the previous protocol of IHC, the immunoreactivity signal was detected using DAB and 
visualised under a Nikon Eclipse E600 microscope, and pictures were taken using a 
Hamamatsu C4742-95 digital camera.  
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2.4. Receptors autoradiography 
2.4.A. Tissue preparation 
Frozen hippocampal blocks obtained from TLE-HS patients and PMC donors were cut 
into 20 µm sections in a coronal plane using cryostat under – 15 to – 19⁰C and mount 
onto gelatin-coated slides and stored at – 80⁰C until assayed. 
 
2.4.B. [3H]-S-zacopride autoradiography 
Receptor autoradiography study of 5-HT3 receptor was conducted by Prof Barnes and 
his colleague using on hippocampal sections obtained from TLE-HS and post-mortem 
control samples. This study was performed as described previously by Parker et al., 
(1996). In brief, frozen sections of the human hippocampus were allowed to equilibrate 
to 4⁰C. The sections were incubated in Hepes/Krebs buffer (mM; Hepes, 50; glucose, 
11; NaCl, 118; NaHCO3, 25; KCl, 4.75; CaCl2, 2.5; KH2PO4, 1.2; MgSO4, 1.2; pH = 7.4) 
for 30 min at 4⁰C in order to decrease the level of endogenous serotonin. 
Subsequently, the slides were incubated for 1 hr with 0.5 nM [3H]-S-zacopride (78 - 83 
Ci/mmol, NEN), to determine the total binding, and in the presence of 1 µM granisetron, 
to define the non-specific binding, at 4⁰C. The slides were then washed in ice-cold 
Hepes/Krebs buffer followed by brief dH2O before dried under a continuous stream of 
cold air. The dry slides then exposed to [3H]-sensitive autoradiography film (Hyperfilm, 
Amersham, UK) in light resistance cassette with [3H] standards (Amersham, UK) for 6 
to 10 weeks. The films were developed using Kodak LX 24 developer and Kodak Unifix 
for 5 min each. The results were quantify using Image Analysis (MCID, Imaging 
Research Inc.). To enhance resolution, the slides were exposed to photographic 
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emulsion (K5 or G5; Ilford) that had been dried onto coverslip before developed the 
photographic emulsion using D19 developer (Kodak, 5 min) and AL4 fixer (Kodak, 5 
min). The result was statistically analysed using unpaired t-test (Prism 5, GraphPad). 
 
2.5. Radioligand binding assays 
2.5.A. 5-HT3 receptors radioligand binding assay 
Hippocampal specimens obtained from TLE-HS patients and PMC donors were snap 
frozen and stored at - 80⁰C. In order to prepare the radioligand binding homogenate, 
the tissue was defrosted in 50 mM Tris buffer (pH = 7.4) and homogenated using 
Polytron blender at 4⁰C. After that, the tissue homogenate was pelleted by 
centrifugation at 48,000 x g for 10 min at 4⁰C and the resulting pellet was resuspended 
in Tris buffer and re-centrifuged to reduce the concentration of the endogenous 5-HT. 
The radioligand binding homogenate was prepared by resuspending the pellet in Tris 
buffer to a final concentration equal to 100 mg/ml according to the original wet weight 
of the tissue. The binding assay was conducted as described previously by Bufton et 
al., (1993). Briefly, duplicate tubes contain 150 µl of 1 nM - 10 µM competing drug 
(ondansetron, S-zacopride and Tropisetron), or 50 mM Tris (pH = 7.4, total binding) 
and 100 µl of ([3H]-granisetron, 0.1 – 10 nM for saturation studies, 0.8 – 1.1 nM for 
competition studies, NEN, 82 – 83.5 Ci/mmol, Perkin-Elmer, Buckinghamshire, UK). 
Ondansetron was used as competing drug in saturation study to determine the non-
specific binding. To initiate the binding, 250 µl tissue homogenate was added to each 
tube and allowed to react for 90 min at room temperature. The reaction was terminated 
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by rapid filtration and washing through Whatman GF/B filters under vacuum. The 
remaining radioactivity on the filters assessed using liquid scintillation. 
 
2.5.B. Single concentration 5-HT3 receptors radioligand binding assay 
In order to detect an approximate density of 5-HT3 receptors in the hippocampus of 
patients with TLE-HS and postmortem control samples, and as a result of the limited 
weight of human tissue samples, a single-concentration radioligand binding assay was 
conducted using 6 nM [3H]-granisetron. The concentration of radioactive granisetron 
was selected based on the radioligand saturation binding assay results which, at 
approximately this concentration, the 5-HT3 receptors in hippocampal homogenate 
begin saturated.  
Human hippocampal tissue was homogenized in 600 µl ice cold Tris buffer (25 mM, 
pH = 7.4) using sonication prior washing with Tris buffer twice at 48,000 x g for 15 min 
(4⁰C) to minimize the level of endogenous 5-HT. The formed pellet was resuspended 
in a fresh Tris buffer. Protein concentration was measured using a Bradford assay 
(TLE-HS = 7 – 12.5 mg/ml; PMC = 2.5 – 14.5 mg/ml). The total binding activity was 
performed in triplicate, and the non-specific (defined by 10 µM ondansetron) was in 
duplicate due to the limited weight of samples. Each tube contained 100 µl Tris buffer 
or ondansetron, 100 µl [3H]-granisetron (approximately 6 nM, Perkin-Elmer, 
Buckinghamshire, UK) and 100 µl hippocampal tissue homogenate. The reaction was 
allowed to be at equilibrium for 1 hr at room temperature, then was terminated rapidly 
by filtration using a GF/B filter (Semat Technical (U K) Ltd, St Albans, UK) presoaked 
in 0.3% Tris/polyethylenimine (Tris/PEI) followed by washing with ice-cold Tris three 
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times. Finally, a 4 ml scintillation fluid (Optiphase HiSafe 2; Perkin Elmer, Waltham, 
Massachusetts, US) was added to each tube, and the level of radioactivity remaining 
on the filter paper was detected using liquid scintillation counting (Tri-carb 1500 TR 
Liquid Scintillation Analyser, Packard). 
 
2.5.C. Radioligand binding assay data analysis 
The saturation binding assay data was analysed using computerised interactive curve 
fitting program (KaleidoGraph, Synergy software, Pennsylvania, US), according to the 
following equation:  
𝑏 = (𝐵𝑚𝑎𝑥×[𝐿]𝑛)/([𝐿]𝑛 + [𝐾]𝑛) 
Where, b = bound radioligand; Bmax = maximum binding activity at equilibrium; L = 
free molar concentration of radioligand; n = Hill coefficient; K = molar equilibrium 
dissociation constant (Bufton, et al., 1993). 
Competing drugs affinity (Ki) calculated according to the following equation:  




Where, IC50 = molar concentration of competing drug that decreases the specific 
binding by 50%; L = free molar concentration of radioligand; Kd = dissociation constant 
of radioligand at equilibrium (Bufton et al., 1993). The saturation binding assay data 
was statistically analysed using unpaired t-test and Single concentration binding assay 





2.6. Total RNA extraction, method development 
2.6.A. Total RNA extraction from FFPE (stained and unstained) samples 
 Total RNA extraction using RNeasy FFPE kit 
In order to extract total RNA from 4 µm thickness FFPE hippocampal sections obtained 
from nine different groups (Table 7), the RNeasy FFPE kit (Qiagen, Manchester, UK) 
was used, based on the manufacturer’s instructions. In summary, the tissue was 
scraped and dewaxed by using xylene, then centrifuged at 15,000 rpm for 2 min to 
pellet the sample. Next, the supernatant was removed and the pellet was washed with 
100% ethanol and pelletted by centrifugation for 2 min at 15,000 rpm. Then, the pellet 
was allowed to dry at room temperature. After that, the pellet was re-suspended in 150 
µl buffer PKD and 10 µl PK, then incubated for 15 min at 56°C in order to activate PK 
to digest the proteins.  
The sample was incubated for another 15 min at 80°C in order to inactivate the PK and 
terminate the digestion. In the next step, the sample was cooled in ice for 3 min and 
then centrifuged for 15 min at 20,000 x g. Next, the supernatant was removed and the 
pellet was re-suspended in DNase buffer and DNase I stock (16 µl and 10 µl, 
respectively) and incubated at room temperature for 15 min. After that, buffer RBC 
(320 µl) and 100% ethanol (720 µl) were added and mixed, then the sample was 
passed through the RNeasy MinElute spin column and centrifuged for 15 sec at 11,000 
x g, followed by 2 min of centrifugation at the same speed after adding 500 µl buffer 




 Total RNA extraction using RNeasy FFPE kit and Poly-A-RNA 
Carrier 
The total RNA was extracted from FFPE samples using the RNEasy FFPE kit (Qiagen, 
Manchester, UK), with a modification based on the manufacturer’s instructions. These 
modifications include using a poly-A RNA carrier (Qiagen, Manchester, UK), which was 
added to the FFPE tissue lysate during the extraction procedure. 
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Table 7. Groups of samples that used for optimising mRNA extraction from IHC stained samples based on staining steps:   
* Group I, subjected to dewaxing procedure followed by RNA extraction.
Group 
number 
Dewaxing and rehydration Antigen retrieve Staining 
dH2O DPC-H2O 
10mM Citric acid pH=6 
20 µg/ml Proteinase K 
pH=8 Rabbit anti-human 
5-HT1A receptors 
In dH2O In DPC-H2O In dH2O In DPC-H2O 
I*        
II √  √     
III  √  √    
IV √    √   
V  √    √  
VI √  √    √ 
VII  √  √   √ 
VIII √    √  √ 
IX  √    √ √ 
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2.6.B. Total RNA extraction from frozen samples 
Three different RNA extraction techniques were conducted in order to identify the most 
suitable method to extract a high quantity and quality of RNA from frozen brain 
samples. These methods included the use of Triazole, the RNeasy Mini Kit, and the 
Triazole/Rneasy Mini Kit. Given the limited number of available human samples, frozen 
rat brain samples were used. 
 
 Total RNA extraction using Triazole 
Approximately 5 mg rat brain tissue was homogenised with 1 ml of Triazole (Ambion 
Life Technologies), then incubated for 5 min at room temperature. At this point, 200 µl 
of chloroform were added and shaken vigorously for 15 sec, then stored at room 
temperature for 7 min before being centrifugated at 12,000 x g for 15 min at 4°C. The 
sample was divided into three layers, with the RNA present in the upper aqueous layer. 
This layer was transferred into RNase-free eppendorf and the RNA was precipitated 
by adding 500 µl of isopropanol (Sigma Aldrich, St. Louis, Missouri, US) and mixed 
gently, then incubated for 5 min at room temperature. After that, the RNA was pelleted 
by centrifugation at 12,000 x g for 8 min at 4°C. Next, the pellet was washed with 75% 
ethanol and centrifugated at 7500 x g for 5 min at 4°C. Finally, the pellet was allowed 
to dry at room temperature for 20 min and then dissolved in RNase-free water 
(PrimerDesign Ltd, Southampton, UK).    




 Total RNA extraction using RNeasy Mini Kit 
The RNA was extracted from approximately 5 mg rat brain using the RNeasy Mini Kit 
(Qiagen, Manchester, UK) according to the manufacturer’s instructions. Briefly, the 
sample was lysated by homogenating the tissue with 350 µl buffer RLT, then 
centrifuged at 15,000 rpm for 3 min. After that, the supernatant was transferred into 
the RNase-free tube and the RNA was precipitated by adding 350 µl of 75% ethanol. 
Next, the sample was passed through the RNeasy MinElute spin column and 
centrifugated at 8000 x g for 15 sec. Then, the 700 µl buffer RW1 was added and 
centrifugated in the same manner as the previous sample. Then, the column was 
washed with buffer RPE and centrifugated for 2 min at 8000 x g. At the end, the RNA 
was collected in 25 µl nuclease-free water. 
 
 Total RNA extraction using Triazole / RNeasy Mini Kit 
This method is mimic the RNeasy Lipid Tissue kit (Qiagen), where the lysate buffer in 
the RNeasy Mini Kit (buffer RLT) was replaced with Triazole and chloroform. This 
extraction was conducted by homogenising approximately 5 mg of frozen rat brain 
samples with 1 ml of Triazole and incubating for 5 min at room temperature followed 
by chloroform for phase separation. After that, the supernatant was transferred into the 
RNase-free tube and the extraction procedure was conducted as previously described 





2.6.C. Optimised total RNA extraction from frozen 
Among these different RNA extraction methods, the most suitable way to extract RNA 
from brain tissue was Triazol / RNeasy mini Kit. The wet weight of each human 
hippocampal samples used was approximately 100 mg. 
 
2.6.D. RNA quantity, purity, and integrity assessment 
The RNA’s quantity and purity was assessed by using the Nanodrop™ 1000 
Spectrophotometer (Thermoscientific, Wilmington, US) in which a 2 µl RNA sample 
was used. The RNA was considered pure RNA if the 260/280 absorption ratio was 
close to 2, according to the manufacturer’s instructions. 
In terms of the RNA’s integrity, the samples were assessed by using the Agilent 2100 
Bioanalyser System (Agilent Technologies, Berkshire, UK), with a 1 µl (5 ng/µl) sample 
used for the very low RNA concentration (< 5 ng/µl). A vacuum concentrator was used 
to concentrate the sample and then it was diluted into the recommended concentration 
using RNA-free water. Based on the manufacturer’s instructions, the RNA integrity 
number (RIN) was in the range of 1 to 10, with the high number representing the higher 
integrated RNA sample. This number represents the ratio between 28S/18S ribosomal 
RNA.   
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2.7. Quantitative reverse transcriptase polymerase chain reaction (qRT-PCR): 
To evaluate the change in the level of expression of mRNA in TLE-HS samples 
compared to PMC, qRT-PCR was conducted in duplex using RNA extracted from the 
hippocampal samples due to the limited amount of extracted materials available. This 
technique was performed using TaqMan Style (hydrolysis probes) primers synthesised 
by PrimerDesign Ltd (Southampton, UK) (Table 8). These primers synthesised close 
to 5’ end. The Precision™ OneStep 2x qRT-PCR MasterMix with low ROX was 
obtained from the same company and the qRT-PCR was performed according to the 
manufacturer’s instructions (Table 9). The housekeeping gens were selected based 
on the comparative study conducted by Maurer-Morelli (et al., 2012). The target genes 
were relatively quantified and statistically analysed using REST2009 (Qiagen, 
Limburg, Netherlands). This software calculates the relative quantification of the 
interest gene based on the efficiency of PCR reaction and the deviation of the crossing 
point of both sample and control group using Pair Wise Fixed Reallocation 










Primer Sequences (position) Probe Sequence (position) 
5-HT1A  GI 











5-HT3A  GI 
Sense primer:  
CAGGGAATGCCAGGGACAT (1656) 
Anti-sense primer:  
GCTTGTGATTGCTGAGATGAATT (1739) 
AAGTCCCGTGCCCTGTTTCCAATGC (1563) 
5-HT4  GI 
Sense primer:  
GGGCATTGAAATCCACTCACT (9) 
Anti-sense primer:  
GCACCACCTTCTCCACTGA (111) 
CCGAAACCCTCCTCAGAACTCACATTAGCAT (91) 
5-HT7  GI 







P2X7  GI 
Sense primer:  
CTTGAAGTTAAAGACTCCTGCTAAAA (14) 
Anti-sense primer:  
GTGACAGCCTCCCTCCCT (142) 
CCACAGCAAGCCCCCTCCCAGTAAC (94) 
GPR61  GI 
Sense primer:  
CTTTCGAATCCCAGGCCAGA (1916) 
Anti-sense primer:  
GCAGGACGGAGGTAGCTG (2014) 
AGCAGCAACTCACCAGCGACATCATC (1963) 
HPRT1  RG 





ENO2  RG 






Target gene symbol Type of gene Accession number Sequence length (bp) 





Table 9. qRT-PCR amplification thermocycler programmes, according to the Precision™ OneStep 2x qRT-PCR MasterMix 
manufacturer instructions 
 
Step Temperature (°C) Time Note 
Reverse transcription 55 10 min 
Steps 3 and 4 repeated for 
40 cycles. 
Polymerase enzyme activation 95 8 min 
Denaturation 95 10 sec 
Data collection 60 60 sec 
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2.8. SDS-PAGE western blot 
2.8.A. Gel preparation 
 Preparation of separating gels 
The gel was prepared a day in advance of the western blot experiment in an acrylamide 
percentage equal to 12 (molecular weight range 10 - 70 kDa), based on the target 
proteins sizes (Table 10). The following components were added in the Falcon tube to 
prepare two gels on the same sequence: 3.35 ml dH2O, 2.5 ml 1.5 M Tris (pH = 8.8), 
100 µl 10% SDS (sodium dodecyl sulphate), 4 ml acrylamide, 50 µl 10% APS 
(ammonium persulfate), and 10 µl TEMED (tetramethylethylenediamine). Then, the gel 
was loaded in the glass casting plate and 200 µl dH2O saturated butanol was loaded 
over to push the gel down and maintain the uniformity of the gel level in each part of 











5-HT3A HTR3A 55 Phosphosite.org A. (n. d.) 
HPRT1 HPRT1 25 Phosphosite.org B. (n. d.) 
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 Preparation of stacking gels 
In order to prepare two stacking gels, the following were added in the falcon tube on 
the same sequence: 3.05 ml dH2O, 1.25 ml 0.5 M Tris (pH = 6.8), 50 µl 10% SDS, 670 
µl acrylamide, 25 µl 10% APS, and 5 µl TEMED. After that, a well-forming comb was 
placed then incubated for 20-30 min until the gel was gelated. Finally, the gels were 
wrapped with cling film and stored in the refrigerator until use.       
 
2.8.B. Protein extraction 
The tissue was harvested with 100 µl Tris buffer (25 mM) by using a sonicator at full 
power for 1-2 seconds. Then, 5 µl tissue homogenate was used to measure the protein 
concentration. A 50 µl tissue homogenate was added to an equal volume of the RIPA 
buffer (radioimmunoprecipitation assay buffer) and mixed well. After that, the laysate 
was mixed with the sample buffer (0.5 M Tris/HCl pH=6.8, 12% [w/v] SDS, 25% [v/v] 
glycerol, 5 mM EDTA, and a small amount of bromophenol blue) that contained 10% 
β-mercaptoethanol. Then, the sample was placed in boiling water for 10 min to 
denature the protein before chilling on ice. 
 
2.8.C. Gel electrophoresis and western blot 
In order to perform gel electrophoresis, the electrophoresis tank was prepared and 
filled with electrophoresis running a buffer that contained 25 mM Tris/HCl pH = 8.3, 
192 mM glycine, and 1% (w/v) SDS. After that, the protein molecular weight markers 
(Color Prestained Protein Standard, Biolab, Ipswich, US) were loaded and protein 
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samples were loaded and electrophoresis was run at a 35 mA constant current, 400 v, 
for 90 min. Later, the gel was removed and allowed to equilibrate in transfer buffer (25 
mM Tris/HCl pH = 8.3, 150 mM glycine, 20% [v/v] methanol, and 0.1% [w/v] SDS) for 
15 min at room temperature. After that, the gel blot was transferred to a PVDF 
(polyvinyl difluoride) membrane (Millipore, Immobilon, Watford, UK) using a semi-dry 
transfer blotter, which ran under a 1.2 mA/cm2 constant current for 1 hour.  
When the transfer was finished, the PVDF membrane was blocked in blocking buffer 
(10% non-fat milk in washing buffer [10 mM Tris/HCl (pH = 7.5), 100 mM NaCl, and 
1% (v/v) Tween 20]) for 2 hours at room temperature. The membrane was then 
incubated with primary antibody diluted in blocking buffer (Table 6) are incubated 
overnight on an orbital shaker. 
The next day, the primary antibody was removed and the membrane was washed 
extensively with washing buffer, before incubation with HRP-linked secondary antibody 
(Table 5) for two hours at room temperature. Later, and after removing the secondary 
antibody, the membrane was washed and covered with ECL solution (Biological 
Industries, Kibbutz Beit-Haemek, Israel) for 5 min at room temperature. The membrane 
was placed in the film cassette and exposed to the Hyperfilm (Hyperfilm MP, 
Amersham) before being developed using an ECOMAX™ X-ray Processor. 
 
2.9. Protein concentration measurement, Bradford protein assay 
A 5 µl of tissue homogenate was used to measure the protein concentration in 1:10 
and 1:100 tissue dilutions prepared in 25 mM Tris/HCl (pH = 7.4). For each sample, 
two cuvettes were used in which 1 ml of Bradford reagent (Sigma Aldrich, St. Louis, 
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Missouri, US) was added per cuvette and mixed with 20 µl of each tissue dilute, 
separately. A third cuvette was used as a blank wherein the tissue homogenate was 
replaced with 20 µl 25 mM Tris/HCl. Five min later, after allowing the dye to reach 
equilibrium, the sample concentration was measured using a spectrophotometer 
(Biophotometer Plus, Eppendorf).  
 
2.10. Data analysis and statistical tests 
The data were analysed by Mann-Whitney U for two groups comparison and Kruskal-
Wallis test followed by Dunn multiple comparison for multiple groups after 
normalisation test was preformed using IBM SBSS statistics 23 software in which the 


















3.1. Experimental research development 
3.1.A. Immunohistochemistry experimental development 
As a result of the limited amount and availability of the human hippocampus, and in 
order to maximise the amount of information that can be obtained from it, two different 
antigen retrieval techniques (HIER [10mM CA, pH= 6] and EIER [20 µg/ml PK, pH= 8]) 
were used in order to examine the possibility of using the same IHC-stained sections 
for other downstream applications such as RT-qPCR. 
 
 Suitability of antigen retrieval techniques 
Heat-induced antigen retrieval was tested on TLE-HS FFPE human hippocampal 
samples using several primary antibodies, and the results show that the HIER 
technique is suitable because it gave a clear immunoreactivity signal with the primary 
antibodies that had been tested. 
The EIER technique was selected for the process in order to prevent the possible 
negative effects of the high temperatures used in the HIER technique on the total 
amount of RNA extracted from the FFPE sections. This technique was optimised with 
a rabbit anti-human 5-HT1A antibody at 37°C for different incubation periods (10, 15, 
20, and 30 minutes) to give a result that was close to the HIER technique without 
detaching the sections from the slides before the compatibility of this technique with 
the other primary antibodies had been tested. 
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The results of the experiment show that there is a relationship between the incubation 
time in the PK and the quality of the immunoreactivity signal of the 5-HT1A receptors. 
However, this relationship was associated with a higher risk of detaching the sections 
from the slides. As a result, the 20-minute incubation time of the slides in PK at 37°C 
was selected as the optimum incubation time (Figure 2). This incubation period 
produced a reasonable immunoreactivity signal compared to the HIER technique, with 
a low risk of tissue detachment from the slides (Figure 3). In terms of signal quality and 
background intensity, the EIER technique was associated with a relatively low 








Figure 2. Effect of proteinase K incubation times on immunohistochemistry 
staining of 5-HT1A receptors in the dentate gyrus of human TLE-HS samples. 
10 minutes (no staining signal); 15 minutes (no staining signal); 20 minutes 












10 min 15 min 





Figure 3. Effect of heat-induced epitope retrieval (boiled citric acid/dH2O, 7 
minutes) and enzyme-induced epitope retrieval (proteinase K/dH2O) on 
immunohistochemistry staining of 5-HT1A receptors in the dentate gyrus of human 
TLE-HS samples. 
 (A) boiled citric acid/dH2O (7 minutes, dark); (B) proteinase K/dH2O (37°C, 20 





 Compatibility of EIER with target protein primary antibodies: 
Regarding the compatibility of the optimised protocol of the EIER technique with 
different anti-human (5-HT1A – 5-HT2A – 5-HT3A – 5-HT4 – 5-HT7) primary antibodies, 
the results, shown in Figure 4, confirmed a strong specific 5-HT2A immunoreactivity 
signal in the hilum of the TLE-HS hippocampal section. On the other hand, a moderate 
specific 5-HT1A immunoreactivity signal was detected in the DG. Furthermore, 5-HT4 
and 5-HT7 receptor-immunoreactivity signals were detected with relatively low and very 
low level, respectively, however, no 5-HT3A signal was detected using this antigen 






Figure 4. Suitability of the proteinase K antigen retrieval protocol for immunohistochemistry with different primary 
antibody staining in the dentate gyrus of human TLE-HS samples. 
5-HT1A antibody (moderate staining signals); 5-HT2A antibody (good staining signals); 5-HT3A antibody (no signals), 5-
HT4 antibody (low staining signals); 5-HT7 antibody (very low staining signals); scale bar = 50 and 100 for 5-HT2A 
staining. 




 Effect of using dH2O and DPC-treated dH2O immunoreactivity 
signals: 
In order to decrease the risk of RNA degradation and increase the yield of total RNA 
extracted from the FFPE sample, the IHC staining buffers and solutions were prepared 
using DPC-treated H2O and processed under nuclease-free conditions. Figure 5 shows 
that replacing dH2O with DPC-treated H2O has some impact on the quality of the 5-HT1A 
immunoreactivity signal depending on the antigen retrieval method that was used. DPC-
treated H2O significantly decreases the background and increases the intensity of the 
specific 5-HT1A immunoreactivity signal in the section that was treated with PK for antigen 
retrieval, compared to the dH2O when it was used to prepare the staining solutions (Figure 
5). On the other hand, DPC-treated H2O significantly decreased the immunoreactivity 
signal of 5-HT1A and slightly improved the background in the section that was subjected 






Figure 5. The effect of using dH2O or DPC-treated H2O with citric acid and 
proteinase K on the immunohistochemistry staining quality of 5-HT1A receptor-
staining in the dentate gyrus of human TLE-HS samples. 







 Polymer Biotin-Tyramide ABC (PBTA) IHC staining technique 
Because there was only a limited amount available of the goat anti-human GPR61 
antibody (generated by a collaborator from the University of Cambridge), this staining 
method was conducted in order to increase the sensitivity of immunohistochemistry 
primary antibodies to the target antigen. The results (Figure 6) show that the sensitivity of 
the signal was increased for approximately 10 times than when DAB only used to enhance 





Figure 6. Effect of DAB and PBTA-DAB staining techniques on the sensitivity of goat anti-human GPR61 antibody to 
recognise the target antigen on human TLE-HS hippocampal samples. Scale bar 50 µm. 
 
1/3000 DAB only 1/6000 DAB only 1/6000 PBTA-DAB 
1/60,000 PBTA-DAB 1/100,000 PBTA-DAB 
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3.1.B. Total RNA extraction 
 Total RNA extraction from FFPE sections 
In order to examine the most suitable method to maximise the RNA yield from the 
samples, the total RNA was extracted from FFPE TLE-HS human hippocampal sections 
using two different methods: the RNEasy FFPE kit and the RNEasy FFPE kit with poly-A 
RNA carrier. In Figure 7, the result does not demonstrate any significant differences 
between the total RNA yields from the FFPE sections when using the RNEasy FFPE kit, 
either with or without using the poly-A RNA carrier (p= 0.45). Furthermore, the addition of 
poly-A RNA carrier did not show any significant improvement on the RNA integrity number, 
which was kept under 3, with and without the carrier (p= 0.239, Figure 8). In terms of the 
effect of using poly-A RNA carrier on the RT-qPCR Ct value of the housekeeping gene 
HPRT1, the result does not show any significant differences between the Ct values of 




























Figure 7. Effects of using poly-A RNA carrier on the RNA yield that was extracted 
from FFPE human TLE-HS hippocampal samples. 



























Figure 8. Effects of using poly-A RNA carrier on the RNA integrity (RIN) on the RNA 
that was extracted from FFPE human TLE-HS hippocampal samples. 



























Figure 9. Effect of using poly-A RNA carrier on the HPRT1 RT-qPCR Ct value of the 
RNA that was extracted from FFPE human TLE-HS hippocampal samples. 




 Effect of IHC staining protocols on total RNA extraction 
Regarding the total RNA quantity that was extracted from IHC-stained and non-stained 
FFPE TLE-HS human hippocampal samples, Figure 10 demonstrates that, among all of 
the 9 different groups that were previously described in table 6, the non-stained group that 
was subjected to PK/dH2O was associated with a significantly higher total RNA yield when 
compared to the rest of the groups (p= 0.02, Figure 10). Moreover, when compared to the 
total RNA yield from non-stained, antigen retrieval only and IHC-stained sections, the 
results show that a significantly higher RNA yield was obtained from the sections that were 
subjected to antigen retrieval without staining (regardless of the type of antigen retrieval 
method), compared to the other groups (p= 0.002, Figure 10). In terms of the differences 
in the yields between the non-stained antigen retrieval only (CA or PK) and IHC-stained 
sections that were subjected to antigen retrieval using CA or PK, the results show that 
sections which were treated with antigen retrieval solutions without staining were 
associated with higher total RNA yields (boiled CA, p= 0.016 and PK, p= 0.025, Figure 
10). 
Regarding the effect of using dH2O or DPC-treated H2O on the total RNA yield, the results 
demonstrate that there are no significant differences among both groups (p= 0.885), or 
between the type of water among the CA and PK groups (p= 0.378 and 0.378, 
respectively). In addition, there were no significant differences between the RNA yield of 
the sections that were exposed to a relatively high temperature (boiled CA) or that were 









Figure 10. The effect of using dH2O or DPC-treated H2O with citric acid and 
proteinase K on the RNA yield extracted from immunohistochemistry staining 
sections. 
n= 3, p ≤ 0.05; star p= 0.002; square p= 0.016; diamond p= 0.025; circle p= 0.02. 
AR= antigen retrieval; CA= citric acid; PK= proteinase K; DPC= DPC-treated H2O. 





 Total RNA extraction from frozen samples 
As a result of the difficulties that were associated with extracting total RNA from fatty tissue 
due to the high fatty acid and triglyceride contents (Hemmrich, et al., 2009, Cirera, 2013), 
and because of the limited amount of fresh and frozen human hippocampal tissue that 
was used in this project, different RNA extraction techniques were used to optimise the 
most suitable extraction method that would produce a higher RNA yield and lower protein 
contamination. In this optimisation procedure, an equal amount of rat brain homogenate 
(approximately 5 mg) was used. The results in Figure 11 show clear difference in the RNA 
yield eluted in a constant total volume (25 µl DPC-treated H2O), based on the method of 
extraction. Compared to the RNEasy mini kit, Triazole was associated with a RNA yield 
(Figure 11) that was six times higher. Interestingly, when combining Triazole and the 
RNEasy mini kit, the yield was increased 2.3 times higher than when RNA was extracted 
by Triazole alone, and 14 times higher when compared to the RNEasy mini kit alone 
(Figure 11). Moreover, combining Triazole with the RNEasy mini kit produces purer RNA 



























Figure 11. The effects of different RNA extraction techniques on the RNA yield from 





























Figure 12. The effects of different RNA extraction techniques on protein 
contamination of the extracted RNA from 5.2 mg of frozen rat brain homogenate. 





3.2. Receptors and protein expression in TLE-HS 
3.2.A. Ligand gated ion channel, 5-HT3 receptors 
 5-HT3A receptors 
o Immunohistochemistry of 5-HT3A receptors expression 
The study of the immunoreactivity of serotonergic ion channel 5-HT3A subunits in the 
hippocampus of TLE-HS patients, compared to post-mortem control samples, revealed 
an upregulation of 5-HT3A subunit among disease samples (Figure 13). This 
overexpression affects the preserved neurons in the dentate gyrus and CA2 (Figure 13). 
Furthermore, a relative increase was found in the remaining neurons of CA3 in TLE-HS 








Figure 13. The immunoreactivity of 5-HT3A receptors in 
hippocampal subfields among TLE-HS patients and age 
match post-mortem control hippocampi. 
Representative result of TLE-HS (n = 11) and PMC (n = 
3): NPNC: No primary negative control hippocampal 
section, NPNC/HC: No primary negative control 
hippocampal section counterstain with hematoxylin. Scale 
bar = 50 µm.  
 
1A 1B 
DG (TLE-HS) DG (PMC) DG (NPNC) DG (NPNC/HC) 
CA4 (TLE-HS) CA4 (PMC) 






Figure 13. continue. 
4A 4B CA2 (TLE-HS) CA2 (PMC) CA2 (NPNC) CA2 (NPNC/HC) 




o SDS-PAGE western blot of 5-HT3A receptors density 
Immunoreactivity of 5-HT3A subunits in the hippocampal lysate of the TLE-HS patients, 
compared to that in the post-mortem controls, expressed an upregulation in TLE-HS 
tissue lysate as assessed by SDS-PAGE western blot (Figure 14). In addition, this 
upregulation was observed in the hippocampal lysate of the TLE-HS samples that were 
subjected to artificial post-mortem delay protocol in comparison to that in the post-mortem 





Figure 14. SDS-PAGE Western Blot of 5-HT3A receptors immunoreactivity in 
hippocampal homogenates from patients with TLE-HS and control donors.  
Also presented are results from hippocampal homogenates from patients with TLE-
HS that were subject to an artificial post-mortem delay (PMD) prior to processing.  
Data from a single experiment is presented, which is representative of five different 
experiments. TLE-HS (n= 8), PMC (n=8) and PMD (n=3). Detection of HPRT1 




o [3H]-S-zacopride autoradiography 
Autoradiography using [3H]-S-zacopride reveal heterogeneity in the level of 5-HT3 
receptors expression within hippocampal subfields between TLE-HS and PMC samples 
(table 10, figure 15). The specific binding activity of [3H]-S-zacopride (non-specific binding 
defined by 1 µM granisetron) reflects the density of 5-HT3 receptors in the hippocampus. 
The result expressed a significant increase in the receptor density in some hippocampal 
areas particularly CA2 (p = 0.0002) and in the molecular layer of the dentate gyrus (p = 
0.0025) among TLE-HS in comparison to PMC samples. The experiments and results 




Table 11. Specific binding activity of [3H]-S-zacopride in the hippocampus of TLE-HS 
patients (n = 9) and PMC samples (n = 10).  
Non-specific binding define by 1 µM granisetron, mean ± SEM, p ≤ 0.05. Data generated 
by Prof Barnes. 
Hippocampal subfields TLE-HS PMC p value 
DG (granular layer) 7.2 ± 0.9 7.3 ± 1.2 0.9486 
DG (molecular layer) 5.6 ± 0.7 2.6 ± 0.5 0.0025* 
CA1 2.4 ± 0.6 1.4 ± 0.3 0.1423 
CA2 10.3 ± 1.1 4.7 ± 0.5 0.0002* 






Figure 15. Expression of 5-HT3 receptors in the hippocampus of TLE-HS patients (n = 9) 
and PMC donor (n = 10).  
Pseudo-colour of [3H]-S-zacopride binding activity in the hippocampus of TLE-HS patients 
(A) and PMC donors (B). C, E; Coverslip dark-field autoradiogram of DG from TLE-HS (C) 
and PMC (E) samples. D, F; histological staining of DG from TLE-HS (D) and PMC (F) 




o Radioligand binding assay 
The saturation studies of 5-HT3 receptors using [3H]-granisetron (0.1 – 10.0 nM) labelling 
hippocampal tissues homogenate express higher specific binding activity (in presence of 
10 µM ondansetron) detected in tissue homogenate of TLE-HS in comparison with PMC 
(table 12, figure 16A). This data generated by Prof Barnes. 
Single concentration radioligand binding assay of the 5-HT3 receptor was conducted using 
6 nM [3H]-granisetron. The result indicates a higher binding level of [3H]-granisetron 
detected in TLE-HS in comparison with postmortem control samples (8.9 ± 1.32, 3.93 ± 
4.9 fmol/mg, respectively, p = 0.0019, mean ± SEM, figure 17). 
The competition studies of [3H]-granisetron (0.8 – 1.1 nM) in presence of some selected 
structurally distinct 5-HT3 receptor ligands display a consistent pharmacological profile of 
the radiolabelled granisetron in TLE-HS compared with PMC tissues homogenate for 




Table 12. Specific binding activity of [3H]-granisetron in the hippocampus homogenate of TLE-HS patients and PMC 
samples.  
Non-specific binding define by 10 µM ondansetron, mean ± SEM, p ≤ 0.05. Data generated by Prof Barnes. 
Sample (n) Bmax (fmol/mg) Kd Hill Coefficient 
TLE-HS (5) 126 ± 10 1.4 ± 0.29  1.01 ± 0.07 
PMC (7) 59 ± 8 1.89 ± 0.8 1.05 ± 0.06 























Figure 16. [3H]-Granisetron saturation binding assays of 5-HT3 receptors within 
hippocampal homogenate from patients with TLE-HS (n = 5) and PMC (n = 7) 
samples.  
The non-specific binding defined by ondansetron (10 µM). Bmax of TLE-HS = 126 ± 
10 fmol/mg and PMC 59 ± 8 fmol/mg, p = 0.0064, mean ± SEM, p ≤ 0.05. Data 
present from single experiment repeated three times. Squares = TLE-HS; Circles = 


































Figure 17. Single concentration [3H]-granisetron binding assay of 5-HT3 receptors 
within hippocampal homogenate from patients with TLE-HS (n = 8) and PMC (n = 8) 
samples.  
The non-specific binding defined by ondansetron (10 µM), Binding level TLE-HS = 
8.9 ± 1.32 fmol/mg and PMC 3.93 ± 4.9 fmol/mg, p = 0.0019, mean ± SEM, p ≤ 0.05. 




Table 13. Pharmacological binding studies of [3H]-granisetron in tissue homogenate 
of TLE-HS (n = 1) and PMC (n = 1) samples.  
Values represent the mean of pKi value from three independent experiments (SEM 





(S)-zacopride 8.97 8.93 
Granisetron 8.20 8.27 
Tropisetron 8.07 8.13 
Ondansetron 7.90 7.93 





o RT-qPCR of 5-HT3A receptors expression 
In terms of the alteration in the level of expression of the 5-HT3A receptors’ subunit mRNA 
in the hippocampus of patients with TLE-HS, the RT-qPCR results showed that there were 
no significant differences between the disease and the control group samples; p = 0.342 
and p = 0.882 were found, respectively, when HPRT1 and ENO2 gene expression were 
used to normalise the results (Figure 18). This result is inconsistence with 5-HT3 receptors’ 
protein studies previously done in this project. 
On the other hand, when the RT-qPCR results for the 5-HT3A receptors’ subunit mRNA 
in the TLE-HS samples that were subjected to a 70 hour post-mortem delay protocol 
(PMD) were compared to the results for the post-mortem delay samples and TLE-HS 
samples that were not subjected to artificial post-mortem delay protocol, it was revealed 
that there was a significant upregulation (approximately 13 folds) of 5-HT3A receptors 
mRNA among PMD samples. The level of significance was p = 0.0007 and 0.001 for the 
PMD samples in comparison to the post-mortem control mRNA when using different 
housekeeping genes, HPRT1 and ENO2, respectively (Figure 19). When comparing the 
PMD to the TLE-HS samples, the result showed a significant overexpression 
(approximately 10–12 folds) of 5-HT3A subunit mRNA in PMD samples (Figure 20). Using 
the HPRT1 gene as a housekeeping gene, the p = 0.02 and p = 0.008 values for the 
statistical evaluation of the RT-qPCR experiment normalised using the ENO2 gene 
(Figure 20). Interestingly, the Ct values of the housekeeping genes, but not target gene, 
were increased in the PMD group compared to other groups by approximately 2 cycles 
for both the HPRT1 and the ENO2 genes. 
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In order to confirm the RT-qPCR results and to assess the risk of fluorescence channel 
bleed with the RT-qPCR fluorescence detection instrument, a RT-qPCR experiment was 
run in monoplex using biological and technical duplicates for 5-HT3A receptors subunit, 
HPRT1 and ENO2 genes, and the result was compared to the duplex RT-qPCR reaction. 
The comparison revealed some increase in the Ct value of 5-HT3A subunit mRNA by 
approximately 1–2 cycles in both the disease and the post-mortem control samples in the 






Figure 18. 5-HT3A receptors subunit gene expression in hippocampus of patients 
with TLE-HS.  
A) 5-HT3A receptors gene expression normalised with the expression of HPRT1 
gene expression (housekeeping gene), TLE-HS n = 7, PMC n = 9, mean ± SEM, p 
= 0.342. B) 5-HT3A receptors gene expression normalised with the expression of 
ENO2 gene expression (housekeeping gene), TLE-HS n = 7, PMC n = 10, mean ± 











Figure 19. 5-HT3A receptors subunit gene expression in hippocampus of patients 
with TLE-HS subjected to approximate 70 hours’ artificial post-mortem delay 
protocol in comparison to post-mortem control.  
5-HT3A receptors gene expression normalised with the expression of HPRT1 gene 
expression, (PMD n = 4, PMC n = 9, p = 0.0007) and normalised with the expression 







Figure 20. 5-HT3A receptors subunit gene expression in hippocampus of patients 
with TLE-HS subjected to approximate 70 hours’ artificial post-mortem delay 
protocol in comparison with TLE-HS samples.  
5-HT3A receptors gene expression normalised with the expression of HPRT1 gene 
expression, (PMD n = 4, TLE-HS n = 5, p = 0.02) and normalised with the expression 




Table 14. Assessment of the qPCR fluorescence channels blood-through risk between target gene (5-HT3A, FAM-
labeled ≈ 520 nm) and housekeeping gene (HPRT1 and ENO2, VIC-labeled ≈ 550 nm). 
Sample 
Monoplex experiment Duplex experiment 

















23.28309 25.37846 23.65804 25.55085 23.62633 







23.57245 26.08395 23.40858 26.40475 23.50788 







23.02981 27.16982 22.76707 26.33833 23.38214 







23.9424 25.68957 23.04241 26.28687 23.9662 
28.64137 23.0284 23.94383 
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3.2.B. Serotonergic G-protein coupled receptors 
 5-HT1A receptors 
o Immunohistochemistry of 5-HT1A receptors expression 
The expression of the inhibitory metabotropic 5-HT1A receptors in the hippocampus of 
patients with temporal lobe TLE-HS was assessed by studying the immunoreactivity of 
these receptors. The result indicated that 5-HT1A receptor expression was increased in 
the hippocampi of patients with TLE-HS compared to age-matched post-mortem control 
hippocampi. This alteration in the level of expression affected predominantly the DG and 
CA2 (Figure 21) of the hippocampus where the neurons were preserved among TLE-HS 
patients. Moreover, in the area where the disease has a relatively strong negative impact 
on the viability of hippocampal neurons (CA4, CA3 and CA1), the result expressed 









Figure 21. The immunoreactivity of 5-HT1A receptors in 
hippocampal subfields among TLE-HS patients and 
age-matched post-mortem control hippocampi. 
Representative result of TLE-HS (n = 11) and PMC (n 
= 3): NPNC: No primary negative control hippocampal 
section, NPNC/HC: No primary negative control 
hippocampal section counterstain with hematoxylin. 
Scale bar = 20 µm. 
 
DG (TLE-HS) DG (PMC) DG (NPNC) DG (NPNC/HC) 
CA4 (TLE-HS) CA4 (PMC) 







Figure 21.  continue. 
 
CA2 (TLE-HS) CA2 (PMC) CA2 (NPNC) CA2 (NPNC/HC) 
CA1 (TLE-HS) CA1 (PMC) 
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o RT-qPCR of 5-HT1A receptors expression 
In order to study the effect of TLE-HS on the expression level of 5-HT1A receptors’ mRNA, 
the duplex RT-qPCR technique was used. This technique was selected due to the limited 
amount of tissue available and the nature of this type of sample to avoid any negative 
effects of the cDNA synthesis procedure on the quality and quantity of the sample. The 
result of the 5-HT1A mRNA expression among TLE-HS patients did not reveal any 
significant differences compared to the age-matched post-mortem control hippocampal 
mRNA (p = 0.185, Figure 22). This result is inconsistence with 5-HT1A receptors’ protein 
expression assessed using immunohistochemistry technique. In the RT-qPCR study, one 
stable housekeeping gene (HPRT1) was used due to the interaction that was detected 







Figure 22. 5-HT1A receptors’ gene expression in hippocampi of patients with TLE-
HS.  
HPRT1 was used as a housekeeping gene (TLE-HS n = 6, PMC n = 9, p = 0.185, 




 5-HT2A receptors 
o Immunohistochemistry of 5-HT2A receptors expression 
The immunoreactivity of the Gq/11 coupled serotonergic receptors (5-HT2A) was studied in 
TLE-HS patients in comparison to post-mortem control hippocampi using 
immunohistochemistry. The results showed that there was a different expression pattern 
of 5-HT2A receptors in different areas of hippocampus of TLE-HS patients compared to 
the post-mortem control samples (Figure 23). The reduced expression affects astrocyte 
cell bodies and processes especially within CA4 (Figure 24) and CA3, in addition to 
apparent neuronal fibres in the hippocampus (Figures 23). Furthermore, 5-HT2A receptors 
were expressed in the regions prove to astrocytosis cells that were observed in all of the 
hippocampal subfields in TLE-HS patients in comparison to post-mortem control. In 
addition, the 5-HT2A receptor positive astrocytes present in the molecular layer of the 
dentate gyrus (Figures 23). 
To phenotype the cells that expressed 5-HT2A receptors, the immunoreactivity of glial 
fibrillary acidic protein (GFAP), a mature astrocyte biomarker, was studied on the adjacent 
sections of those immunologically stained slides to detect the expression of 5-HT2A 
receptors. The results revealed that the immunoreactivity of both 5-HT2A receptors and 
GFAP filaments were approximately co-localised on hippocampal astrocytes; however, 
the level of expression of GFAP in the astrocyte cell bodies of the disease samples was 
less than in the control samples (Figure 25).  
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Interestingly, the astocytes in the CA4 region of TLE-HS samples show relatively high 5-
HT2A receptor expression compared to that in the molecular layer of the dentate gyrus 
(Figure 25). On the other hand, GFAP is highly expressed in the molecular layer of the 









Figure 23. The immunoreactivity of 5-HT2A receptors in 
hippocampal subfields among TLE-HS patients and 
age match post-mortem control hippocampi. 
Representative result of TLE-HS (n = 11) and PMC (n 
= 3): NPNC: No primary negative control hippocampal 
section, NPNC/HC: No primary negative control 
hippocampal section counterstain with 
hematoxylin.Scale bar = 50 µm. 
 
DG (TLE-HS) DG (PMC) DG (NPNC) DG (NPNC/HC) 
CA4 (TLE-HS) CA4 (PMC) 








Figure 23.  continue. 
CA2 (TLE-HS) CA2 (PMC) CA2 (NPNC) CA2 (NPNC/HC) 




Figure 24. Immunoreactivity of 5-HT2A receptors in astrocytes of human 
hippocampus CA4. 
A) TLE-HS hippocampal sample, B) post-mortem control hippocampus. Scale bar: 




Figure 25. Immunoreactivity of 5-HT2A receptors and GFAP astrocytes biomarker in the adjacent sections in CA4 and 
dentate gyrus of human hippocampus.  
A) post-mortem control hippocampus, B) TLE-HS hippocampal sections, Right: 5-HT2A immunoreactivity, Left: GFAP 
immunoreactivity. Scale bar: 50 µm and 100 µm. DG: dentate gyrus. 
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o RT-qPCR of 5-HT2A receptors expression 
The expression of the mRNA of the 5-HT2A receptors, a RT-qPCR experiment was 
conducted that did not reveal a change in expression from the TLE-HS disease on the 
mRNA of the receptors; p = 0.404 and p = 0.75 were found when the level of expression 
was normalised using HPRT1 and ENO2 gene expression, respectively (Figure 26). The 





Figure 26. 5-HT2A receptors subunit gene expression in hippocampus of patients 
with TLE-HS.  
A) 5-HT2A receptors gene expression normalised with the expression of HPRT1 
gene expression (housekeeping gene), TLE-HS n = 6, PMC n = 8, mean ± SEM, p= 
0.404. B) 5-HT2A receptors gene expression normalised with the expression of 
ENO2 gene expression (housekeeping gene), TLE-HS n = 6, PMC n = 9, mean ± 
SEM, p = 0.750. 
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 5-HT4 receptors 
o Immunohistochemistry of 5-HT4 receptors expression 
In order to study the involvement of the Gs protein coupled receptors (5-HT4) in the 
pathogenesis of TLE-HS, the immunoreactivity of these receptors was examined in the 
hippocampi of TLE-HS patients compared to post-mortem control samples. The results 
revealed an apparent increased expression of these excitatory receptors in disease group 
samples compared to the post-mortem control hippocampi (Figure 27). This increase was 
detected in dentate gyrus and CA2 of the TLE-HS diseased hippocampi, where the 
neurons are relatively preserved from the negative effect of disease in the hippocampus 
(Figure 27). Whereas, no differences in immunoreactivity were observed in the other 













Figure 27. The immunoreactivity of 5-HT4 receptors in 
hippocampal subfields among TLE-HS patients and 
age-matched post-mortem control hippocampi.  
Representative results of TLE-HS (n = 11) and PMC 
(n = 3): NPNC: No primary negative control 
hippocampal section, NPNC/HC: No primary negative 
control hippocampal section counterstain with 
hematoxylin. Scale bar = 50 µm. 
 
DG (TLE-HS) DG (PMC) DG (NPNC) DG (NPNC/HC) 
CA4 (TLE-HS) CA4 (PMC) 







Figure 27.  Continue.
CA2 (TLE-HS) CA2 (PMC) CA2 (NPNC) CA2 (NPNC/HC) 
CA1 (TLE-HS) CA1 (PMC) 
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o RT-qPCR of 5-HT4 receptors expression 
The effect of the disease on the 5-HT4 receptors’ mRNA, the result does not reveal any 
significant differences between the disease and post-mortem control hippocampal 
samples (Figure 28). The same result was observed when two different housekeeping 
genes (HPRT1, ENO2) were used to normalise the data (p= 0.281 and p= 0.650, 
respectively, Figure 28). This expression of 5-HT4 receptors’ mRNA is inconsistence with 




Figure 28. 5-HT4 receptors’ gene expression in hippocampi of patients with TLE-
HS. 
A) 5-HT4 receptors gene expression normalised with the expression of HPRT1 gene 
expression (housekeeping gene), TLE-HS n = 4, PMC n = 4, p= 0.281, mean ± SEM. 
B) 5-HT4 receptors gene expression normalised with the expression of ENO2 gene 
expression (housekeeping gene), TLE-HS n = 6, PMC n = 8, p= 0.650, mean ± SEM. 
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 5-HT7 receptors 
Immunoreactivity studies of the 5-HT7 receptors were conducted using TLE-HS and post-
mortem control samples. The results generated did not indicate well-defined 
immunoreactivity signals in either the diseased or the control samples (some non-specific 




3.2.C. Orphan G-protein, GPR61 
The orphan G protein (GPR61) immunoreactivity results indicate that this protein is 
normally present in the neuronal cell membrane in the form of small immunoreactive dots 
(Figure 29). These signals are highly expressed in CA1, CA2 and CA3 of post-mortem 
control hippocampi (Figure 30). In addition, this orphan G-protein is moderately expressed 
in granular cells of the dentate gyrus and CA4 (Figure 30). 
In terms of the alteration in the expression of GPR61 protein among diseased samples, 
the results revealed that there is a relatively moderate upregulation of GPR61 in the 
dentate gyrus, CA2 and in the remaining neurons of the CA3 in the TLE-HS hippocampi 
in comparison to the post-mortem control samples (Figure 31). Moreover, this protein 
expressed a slight upregulation in CA1 of the TLE-HS samples (Figure 31). Inconsistency, 
the gene expression of GPR61 mRNA did not reveal significant differences between the 
diseased and post-mortem control samples, p = 0.231 (Figure 32). 
An interesting observation was made in one of the TLE-HS surgically resected 
hippocampi. In this sample, unknown neuronal inclusion bodies positively reacted with the 
GPR61 protein antibodies present in the CA1 neuronal cells of the hippocampal subfield 








Figure 29. Localisation of GPR61 protein, present as small brown immunoreactive dots, 
in the cell membrane of pyramidal neurons of normal hippocampal CA1. 




Figure 30. The immunoreactivity of GPR61 protein in hippocampal subfields in normal post-mortem control 
hippocampi, PMC (n = 3, representative result of 5 different experiments).   
A) GPR61 protein immunoreactivity. Left; pre-hematoxylin counterstain. Right; post-hematoxylin counterstain. B) 
Histological staining and the localisation of the selected immunoreactivity signals.  C) No primary negative control 
counterstained with hematoxylin. High signal; CA3, CA2 and CA1, Moderate signal; Dentate gyrus, Low signal; CA4 









Figure 31. The immunoreactivity of GPR61 protein in 
hippocampal subfields among TLE-HS patients and 
age match post-mortem control hippocampi. 
Representative result of TLE-HS (n = 11) and PMC (n 
= 3): NPNC: No primary negative control hippocampal 
section, NPNC/HC: No primary negative control 
hippocampal section counterstain with hematoxylin. 
Scale bar = 50 µm. 
 
DG (TLE-HS) DG (PMC) DG (NPNC) DG (NPNC/HC) 
CA4 (TLE-HS) CA4 (PMC) 









Figure 31. continuous. 
CA2 (TLE-HS) CA2 (PMC) CA2 (NPNC) CA2 (NPNC/HC) 







Figure 32. GPR61 protein gene expression in hippocampus of patients with TLE-
HS.  
A) GPR61 protein gene expression normalised with the expression of HPRT1 gene 
expression (housekeeping gene), TLE-HS n = 6, PMC n = 9, mean ± SEM, p= 0.231. 
B) GPR61 protein gene expression normalised with the expression of ENO2 gene 





Figure 33. GPR61 protein positive neuronal inclusion bodies in neuronal cells in 
CA1 in one of TLE-HS hippocampal samples.  




3.2.D. Purinergic ion channel, P2x7 receptors 
The study of the excitatory ligand gated purinergic ion channel immunoreactivity indicated 
an upregulation of P2x7 receptors in the dentate gyrus and CA2, where the neurons were 
preserved from the disease’s negative effect on neuronal cells viability in comparison to 
the post-mortem control hippocampi (Figure 34). Furthermore, the immunoreactivity signal 
showed a slight overexpression of P2x7 in CA3 and CA1 with respect to neuronal loss in 
the diseased samples (Figure 34).  
Regarding the P2x7 receptors’ gene expression, the results (inconsistence to protein 
expression) do not show any significant change in the TLE-HS patients in comparison to 









Figure 34. The immunoreactivity of P2x7 receptors in 
hippocampal subfields among TLE-HS patients and 
age match post-mortem control hippocampi.  
Representative result of TLE-HS (n = 11) and PMC (n 
= 3): NPNC: No primary negative control hippocampal 
section, NPNC/HC: No primary negative control 
hippocampal section counterstain with hematoxylin. 
Scale bar = 50 µm. 
 
DG (TLE-HS) DG (PMC) DG (NPNC) DG (NPNC/HC) 
CA4 (TLE-HS) CA4 (PMC) 







Figure 34.  Continue. 
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Figure 35. P2x7 receptors gene expression in hippocampus of patients with TLE-
HS. 
The P2x7 receptors gene expression normalised with the expression of ENO2 gene 

















4.1. Experimental optimization 
4.1.A. Immunohistochemistry 
Due to the limited number of human hippocampal samples, the IHC optimisation 
processes were conducted to maximise the amount of information that could be obtained 
from each sample. Thus the most suitable IHC staining protocol to give a specific 
immunoreactivity signal without affecting the RNA samples, which could then be used to 
study the effect of this disease on the expression of target receptors and protein mRNA. 
This also provided a direct correlation between the expression of the target proteins and 
the mRNA level. The results of the optimisation process with the different antigen retrieval 
techniques demonstrate the suitability of using HIER – for de-masking the antigen on the 
human hippocampal samples – to study the expression of the target protein using the 
selected antibodies (Table 5) and giving a strong, specific signal to each antibody. 
Regarding the use of the optimised EIER protocol, this resulted in a strong, specific 
immunoreactivity signal when used to recover the antigens to allow detection of 5-HT2A 
receptor. This indicated that EIER can be employed to study the expression of 5-HT2A 
receptors using this antibody. Furthermore, a reasonably moderate signal of 5-HT1A 
receptor was detected using this method. For this reason, and because of the limited 
amount of the mouse anti-human 5-HT2A antibody – which is no longer synthesised – the 




This enzyme protocol was associated with some effects on the immunoreactivity signal of 
the tested antibody (5-HT1A). These included a reduction in the IHC signal and a relative 
reduction in the background; however, when this experiment was run under nuclease-free 
conditions, the immunoreactivity signal increased and the background decreased. This 
suggests that EIER could produce an improved result when the protocol is conducted 
under nuclease-free conditions.  
Regarding the increase of the sensitivity of the GPR61 immunoreactivity signal using the 
PBTA-DAB technique, the result showed an increase in GPR61 antibody sensitivity, with 
a negative effect on the resolution of the signal. The loss of the signal resolution limited 
the use of this technique to localise the GPR61 protein in brain tissue samples using this 
antibody (goat anti-human GPR61 antibody, C-terminus, GT2-135). Nevertheless, this 
staining involved a combined technique including polymer and DAB, and it could be used 
to enhance the sensitivity of low-sensitivity primary antibodies. 
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4.1.B. Total RNA extraction 
 FFPE hippocampal samples 
In terms of extracting RNA from FFPE hippocampal samples, the use of the poly-A-RNA 
carrier failed to have a positive impact on the yield or integrity of the extracted RNA. In 
addition, no improvement was detected in the Ct value of the RT-qPCR of the 
housekeeping gene (HPRT1). These results could be due to the severe level of 
degradation of the extracted RNA, which made the detection of differences is difficult. The 
degradation and low yield may have been due to the following: a) the tissue fixation 
method (FFPE), b) the type of tissue (adipose tissue), which adds more challenges for 
extracting RNA, c) the thickness of the sections (4 µm), or d) the storage conditions (room 
temperature). These factors can accelerate the rate of degradation of cellular RNA. 
Regarding to the effect of IHC staining protocols on the RNA yield, the antigen retrieval 
step was associated with unexpected effect on the RNA yield; this yield was significantly 
increased, especially when PK/dH2O was used for antigen retrieval without staining. It 
seems to be essential to perform this step before extracting RNA from FFPE brain 
samples. Interestingly, the staining process that followed the antigen retrieval caused a 
strong negative effect on the RNA yield from the FFPE stained slides. This effect on the 
RNA yield may explain the harmful effect of IHC staining chemicals on the cellular RNA.  
There were no differences in the effect of using DPC-treated H2O on RNA yield under 
nuclease-free conditions compared to when the RNA was extracted regardless of 
nuclease-free conditions and solutions. This may be due to the sever degradation level of 
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RNA that affected by the fixation method (FFPE), tissue thickness and storage time and 
condition. 
 
 Frozen brain samples 
To maximise the amount of mRNA extracted from the limited—and thus highly precious—
number of human hippocampal samples, alternate RNA extraction methods were 
examined using equal amounts of rat brain homogenate. Results indicated that Triazole 
acts as a powerful solubilising agent, capable of dissolving the plasma membrane of brain 
tissue samples containing high concentrations of fatty acids and triglycerides (Cirera, 
2013; Hemmrich, et al., 2009). Thus, Triazole causes an increase in the amount of RNA 
extracted from a sample. Disadvantages of Triazole compound use involve the risk of 
protein contamination and the presence of a negative safety profile. However, use of an 
RNEasy mini column to clean the aqueous layer of Triazole-containing RNA produced a 
high yield and pure RNA sample. Therefore, a protocol was developed involving the 
combined use of Triazole and RNEasy mini kits to extract RNA from human hippocampal 
samples.  
 
The work on the extracted RNA from FFPE samples had been stopped due to the arriving 




4.2. Receptors and protein expression in human TLE-HS hippocampal samples 
The present studies investigated potential druggable targets within hippocampus that can 
be used to control seizures in TLE-HS patients. These studies focused on the involvement 
of some excitatory and inhibitory serotonergic receptors (5-HT1A, 5-HT2A, 5-HT3A, 5-HT4 
and 5-HT7) in TLE-HS with more emphasis on the clinically important ionotropic excitatory 
receptor (the 5-HT3 receptor). In addition, some interesting non-serotonergic targets 
(GPR61 and P2x7), which are poorly understood in this type of epilepsy were also 
investigated since suitable antibodies were available in the laboratory due to other 
projects. The laboratory investigation of these targets revealed the following; 
 
4.2.A. Ligand gated ion channel, 5-HT3 receptors 
 5-HT3A receptors 
Ionotropic excitatory serotonergic 5-HT3 receptors were studied due to their important 
physiological and pathological role in the human brain. This study is complementary to 
the work done previously in Professor Nicholas Barnes’ laboratory. The 5-HT3A receptor 
subunit is the critical subunit to convey function of the 5-HT3 receptor. The 5-HT3A 
receptor subunit can form a pentameric homomeric 5-HT3A receptor, or can be combined 
with other 5-HT3 receptor subunits (3B, 3C, 3D and 3E subunits) to form a heteromeric 5-
HT3 receptor (Niesler et al., 2008). The best studied heteromeric 5-HT3 receptors are the 
5-HT3AB receptors, that are pharmacologically identical to 5-HT3A receptors, yet have 
greater single channel conductance and are relatively less permeable to Ca2+ (Davies et 
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al., 1999).  The immunoreactivity of 5-HT3A receptor subunits in hippocampal samples 
obtained from TLE-HS patients was examined using immunohistochemistry techniques 
and compared with hippocampal samples from post-mortem ‘controls’ (ie individuals who 
had died without a neurological or psychiatric disorder). There was a clear upregulation in 
the 5-HT3A-immunoreactivity within the resected hippocampi from patients with TLE-HS. 
This overexpression primarily affected granular cells of the dentate gyrus and pyramidal 
neurons of the CA2 field, as well as the CA3 field. This clear change in levels of 
immunoreactivity was unlikely to simply represent a difference in the ‘post-mortem’ delay 
(for the control tissue the period of time from death until the hippocampal tissue was 
cryopreserved, whereas for the resected hippocampi the time from surgical resection to 
cryopreserving the tissue) since the difference in immunoreactivity was also evident after 
subjecting the resected hippocampal tissue from patients with TLE-HS to an artificial post-
mortem delay to better mimic the delay necessitated to obtain the tissue from the control 
donors. This result likely excludes the possible negative biological effect of the post-
mortem condition on protein expression. This finding is parallel to the data generated by 
Professor Barnes, where a 5-HT3 receptor expresses an upregulation in the molecular 
layer of the dentate gyrus, as a result of pathological granular cell migration and mossy 
fiber sprouting from dentate granular layer, and the CA2 of the hippocampus of TLE-HS 
patients using 5-HT3 receptor autoradiography. Moreover, this increase in receptor 
binding activity appears due to an increase in 5-HT3 receptor density rather than an 
increase in the affinity of the radioligand ([3H]-granisetron) for the receptor in diseased 
samples, which were examined using saturation binding studies and followed up with 
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single concentration radioligand binding assays to assess the levels of 5-HT3 receptor 
binding in the hippocampal tissue from controls and patients with TLE-HS. 
Within the hippocampus, the excitatory 5-HT3 receptor is normally expressed in pyramidal 
neurons (Brady et al., 2007) and GABAergic interneurons (Tecott et al., 1993; Morales 
and Bloom, 1997), and it is detected at a very low level in dentatal granular cells (Brady 
et al., 2007). This receptor modulates neurotransmitters’ (especially glutamate and GABA) 
release in the hippocampus (Pehrson and Sanchez, 2014). The activation of this receptor 
increases the cellular excitability and firing of neuronal cells (Nicholas and Nicholas, 
2008). In the hippocampus, excitatory pyramidal neurons integrate hippocampal 
information and transfer its outputs to different brain regions (Graves et al., 2012). These 
principle neurons received tens of thousands of stimulatory and a few thousand inhibitory 
synaptic neurotransmitters (Megias et al., 2001). Similar to the pyramidal neurons, fully 
developed dentate granular cells received an excitatory input that was predominantly 
glutamate and produced a synaptic glutamatergic response on the neuronal cells of the 
hippocampal CA3 (Gomez-Lira et al., 2005). This response was preserved even after the 
transient upregulation of GABA that results from continuous neuronal excitability during a 
seizure (Gomez-Lira et al., 2005). 
The consistent findings of upregulated 5-HT3 receptors in the hippocampus of TLE-HS 
patients in comparison to control samples strongly suggest that the upregulation of the 
excitatory 5-HT3 receptors in the excitatory pyramidal and granular neurons may 
contribute to the seizure activity in the sclerotic hippocampus of TLE-HS patients. 
Therefore, the 5-HT3 receptor could be proposed as a potential novel target to antagonise 
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in order to control seizures in this type of epileptic patient. There are a number of 5-HT3 
receptor antagonists marketed for clinical conditions (e.g. cancer chemotherapy-induced 
emesis, post-operative nausea and vomiting; Garrett et al., 2003), which may allow the 
testing of such drugs in an attempt to broaden their therapeutic utility. Indeed, there are 
already a number of ‘off-label’ uses of 5-HT3 receptor antagonists, such as to relieve 
chronic fatigue syndrome and fibromyalgia (Tolk et al., 2004). 
Normally with such a potential identified, a logical next step would be to assess the action 
of the potential therapeutic within an animal model. Unfortunately, there are no good 
animal models of TLE-HS – since in the human condition patients tend to be refractory to 
drug treatment, hence the need for surgical intervention – yet in proposed animal models 
a number of anti-epileptic drugs display efficacy, hence deviating from the human clinical 
condition. According to Sloviter (2008) chemo-induced SE in rodents (e.g. the lithium-
pilocarpine rat model) is associated with high mortality rates and the surviving animal 
exhibits less severe seizure activity. Moreover, a variable degree of histological damage 
in the hippocampus (more often limited damage) is observed among the surviving 
animals; however, extrahippocampal damages are more pronounced in this type of animal 
model (Sloviter, 2008). The significant extrahippocampal changes and the limited 
hippocampal damage indicate that extrahippocampal neurons could be the source of the 
continuous SE activity (Sloviter, 2008). Different to chemo-induced SE, electric shock-
induced SE is not associated with a high mortality rate or extrahippocampal damages. 
Nevertheless, interpreting the electrophysiological recording of an animal brain is more 
difficult as a result of the presence of the implanted electrodes, which are themselves 
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considered a brain injury (Sloviter  and Bumanglag, 2013). A further complication arises 
due to the cellular expression of the 5-HT3 receptor within the rodent hippocampus. Thus 
within the rodent hippocampus, 5-HT3 receptor expression is restricted to GABAergic 
interneurons (Tecott et al., 1993; Morales and Bloom, 1997), whereas in human 
hippocampus, 5-HT3 receptor expression is also evident in the excitatory glutamate 
neurons (pyramidal neurons and dentate gyrus neurons; Brady et al., 2007; present 
studies). Indeed, throughout the forebrain of rodents, the pattern of 5-HT3 receptor 
expression differs to humans (Barnes et al., 1989; Parker et al., 1996). Therefore, this 
further negates the benefit of testing the action of a 5-HT3 receptor antagonist in a rodent 
model of TLE-HS.  
In spite of the issues associated with animal models, the effect of a 5-HT3 receptor 
antagonist was studied on the lithium-pilocarpine rat model. The result revealed that 
ondansetron (a 5-HT3 antagonist) protects animals from seizures (Kasture and Kasture, 
1999). Moreover, in comparison to phenytoin (an anticonvulsant drug acting as a voltage-
gated sodium channel blocker), ondansetron alone or in combination with phenytoin 
exhibits higher anticonvulsant activity on the electric shock-induced SE rat model 
(Balakrishnan et al., 2000).  
Despite these interesting results, the extrapolation of these data from animal models to 
patients with TLE-HS is questioned due to the differences in the expression pattern of the 
5-HT3 receptor between human and rodents’ hippocampi (Tecott et al., 1993; Morales and 
Bloom, 1997; Brady et al., 2007), in addition to the limitations of the animal models 
(Sloviter, 2008; Sloviter  and Bumanglag, 2013).  
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In vitro electrophysiological studies of the effect of antagonising 5-HT3 receptors on the 
seizure activity of resected hippocampi from TLE-HS patients may assess the possibility 
of using such medications to control seizures among TLE-HS patients. However, such 
type of studies associated with some limitations that affect the interpretation of the results. 
These limitations are including; 1) absence of neuorotransmitters and modulators inputs 
and outputs received from and to the resected hippocampus from other brain areas, 2) 
risk of neuronal ischemia and hypoxia on the resected hippocampus due to lack of blood 
circulation, 3) neurotrauma as a result of surgical resection and slicing procedure, 4) short 
lifespan of sliced neuronal block (Xiong and Xia, 2014). Therefore, the results of this type 
of study could be questioned. However, in this research project, electrophysiological 
recordings of hippocampal tissue resected from patients with TLE-HS were attempted (5 
patients, data not present). However, despite indications of neuronal electrical activity 
being recorded, no clear and consistent results were obtained, potentially due to some of 
the issues raised above. Nevertheless, the positive results of present project concerning 
the upregulation of the excitatory 5-HT3 receptor by surviving excitatory hippocampal 
neurons within the hippocampus of patients with TLE-HS (Table 15), along with the 
availability of marketed safe and selective 5-HT3 receptor antagonists (e.g. granisetron), 
affords the opportunity to assess the potential therapeutic utility of 5-HT3 receptor 
antagonists to reduce epileptic episodes of patients with TLE-HS. According to the 
pharmacological study of different 5-HT3 receptor antagonists presented in this project, 
the result reveals a compatible affinity for the target receptor between TLE-HS and PMC 
samples for the drugs investigated in this study. Such data facilitates the selection of the 
drug candidate for use in a clinical study of patients with TLE-HS.  
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The suggested plan for the phase II clinical trial is to start with a small number of clinically 
diagnosed TLE-HS patients (n = 10), to enter a phase IIa pilot study. The proposed 
candidate drug to use in this study is granisetron. The rationale for this selection is that 
clinical grade generic granisetron is available in the UK (Palliativedrugs.com, 2008) and 
the drug is considered a better 5-HT3 receptor antagonist to use over ondansetron due to 
greater selectivity for the 5-HT3 receptor. Furthermore, to our knowledge, granisetron has 
at least a lower tendency to cause seizures in its own right (a rare side effect of some 5-
HT3 receptors antagonists e.g. ondansetron). Granisetron was reported to be possibly 
involved in a few case reports of seizures regarding pediatric patients receiving 
polypharmacy, including some drugs that have the known tendency for seizure activity, 
such as opioids, such that a specific role for granisetron is difficult to assess. However, 
because of this potential for 5-HT3 receptor antagonists to cause seizures, it is 
recommended that a carefully monitored dose ranging ‘safety’ study in patients with TLE-
HS is first initiated. 
Under close clinical monitoring, a group of five TLE-HS patients will receive low dose 
granisetron (0.25 mg bid) in addition to standard treatment. If this dose of granisetron is 
well tolerated for a week, the dose would be elevated to 0.5 mg bid for a further week. In 
the absence of concerns over the granisetron medication, the dose would then be 
elevated to 1.0 mg bid for a further week. The plasma concentrations of granisetron will 
be monitored during this safety trial. Whilst the primary endpoint is to assess safety, the 
use of seizure diaries and with additional information from carers, any potential efficacy 
would also be assessed.  
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If the initial safety trial reached a primary end point of no adverse safety profile, then a 
subsequent more extensive study aimed at assessing efficacy as a primary endpoint 
would be warranted. This latter study (phase IIb) would take the form of a double blind 
placebo-controlled cross over study of granisetron (1.0 mg bd) in patients with TLE-HS for 
three months with a further three months following treatment crossover. Seizure incidence 
and any patient-reported side effects would be assessed by a patient diary. In addition, 
plasma concentrations of granisetron would be recorded periodically along with a 
standard set of physiological and biochemical assessments designed to monitor potential 
side-effects resulted. The primary endpoints of this study will be a reduction in seizure 
frequency and/or severity. By utilizing patients that were pre-selected for surgical 
intervention a clear diagnosis and results from a battery of tests would allow some degree 
of harmonization in the patients in terms of their TLE-HS, which may facilitate positive 




Table 15. Assessment of the 5-HT3 receptors expression in the hippocampus of patients 
with TLE-HS using different experimental techniques: 
  
Assessment technique 
5-HT3 receptors expression level 
in TLE-HS patients 
Homogenate radioligand binding assay of [3H]-
granisetron 
Increase 




SDS-PAGE western blot Increase 




The positive results obtaining concerning the upregulated expression of 5-HT3 receptors 
in the hippocampus of patients with TLE-HS focussed attention upon the potential 
dysfunction of the 5-HT system in TLE-HS. Hence, a broader assessment of 5-HT function 
in TLE-HS was initiated. This included assessing the expression of other 5-HT receptor 
subtypes as detailed below. 
 
4.2.B. Serotonergic G-protein coupled receptors 
 5-HT1A receptors 
Whilst the 5-HT3 receptor is a LGIC, all the other 5-HT receptor subtypes are G-protein 
coupled receptors (GPCRs). The first 5-HT GPCR investigated in the present study was 
the Gi-protein coupled 5-HT1A receptor. Further rationale for study of the 5-HT1A receptor 
in TLE-HS is the well-recognised comorbidity between epilepsy and depression in some 
epileptic patients. The comorbidity has been reported to be present in 11% of the patients 
with epilepsy (Lothe et al., 2008). This percentage increases to around 60% among 
patients with recurrent seizures. Depression is frequently observed among patients with 
TLE-HS, especially when TLE-HS affected the left hippocampus (Altshuler et al., 1990; 
Quiske et al.; 2000; Jones et al., 2005). Hence the well-recognised role of the 5-HT1A 
receptor with respect to depression adds rationale to the study of this receptor in TLE-HS. 
The results of this project revealed an upregulation of 5-HT1A receptors among TLE-HS 
hippocampal samples compared to the age-matched control hippocampi. The 
pathological change in the expression of these inhibitory receptors’ expression might be 
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a physiological compensatory mechanism to adapt the hyper-excitable neuronal activity 
in the hippocampus (or indeed vice versa). Interestingly, no significant alteration in the 
receptor mRNA was observed in the disease samples compared to the control 
hippocampi. 
To the best of our knowledge, there is no scientific data about the correlation between the 
5-HT1A receptor density at the molecular level and the binding activity in the hippocampi 
of patients with TLE-HS in comparison to age-matched post-mortem control samples, 
except those conducted using positron-emission tomography (PET). These studies were 
conducted using either high affinity 5-HT1A receptors’ antagonists such as [18F]FCWAY 
(Toczek et al., 2003, Giovacchini et al., 2005, Theodore et al., 2007) and [11C]WAY-
100635 (Savic et al., 2004, Parsey et al., 2006 and Assem-Hilger et al., 2010), or a low 
affinity ligand, e.g., [18F]MPPF (Lothe et al., 2008), which has a close affinity to that of 5-
HT in order to allow the endogenous 5-HT to bind to the 5-HT1A receptors, (table 16). 
According to Savic (2004) and Assem-Hilger (2010), the ligands’ binding activity was 
significantly lower among TLE-HS patients free from major depression disorder (MDD) 
using high affinity 5-HT1A receptors’ ligands. Moreover, data generated by Hasler et al. 
(2007) in antidepressant-naive patients with TLE-HS comorbid with MDD (TLE-HS/MDD) 
show a significant reduction in 5-HT1A receptors binding activity. The comparable findings 
were observed among antidepressant-naïve MDD patients (Hirvonen et al., 2008). These 
results may support the hypothesis that there is a contribution from TLE-HS and MDD that 
underlies the pathological mechanisms (Hasler et al., 2007). Although, the TLE-HS 
samples in this project are obtained from anti-depressant naïve donor (except one), 
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however, no apparent difference in receptors immunoreactivity was observed among anti-
depressant naïve and the one whose exposed to anti-depressant medication. Based on 
these data, the upregulation of the 5-HT1A receptors that observed in our study requires 
the need for further in vitro laboratory investigation to the binding activity of this inhibitory 
receptor using diseased and control human hippocampal homogenate. Saturation 
radioligand binding assays with relevant tissue homogenates would help address the 
pathological alteration in the 5-HT1A receptors affinity to the radio-labeled ligand and the 
receptor density in TLE-HS and PMC samples. Such a study would allow a better 
understanding of the involvement of this inhibitory receptor in TLE-HS.  
In contrast to these finding, results were observed in antidepressant-naïve TLE-HS 
comorbid with MDD (Lothe et al., 2008) and in MDD patients (Parsey et al., 2006) by using 
low and high affinity 5-HT1A receptor’s antagonist, respectively, expressed an increase in 
the receptors binding activity. These results are in parallel to the inverse relationship 
between chronic treatment using serotonergic anti-depressant agents and the binding 
activity of 5-HT1A receptors (Gray et al., 2013).  The results of the upregulation of 5-HT1A 
receptors’ immunoreactivity in TLE-HS hippocampal sections, compared with age-
matched post-mortem controls identified in this study, can give a possible explanation of 
the higher binding activity of different 5-HT1A receptors’ antagonists that were observed in 
these PET studies of the antidepressant-naive TLE-HS/MDD and MDD patients.  
One of the pathological effects that may result from the upregulation of the 5-HT1A 
receptors in the hippocampus of a TLE-HS patient is memory impairment, which was 
clinically observed in some of the TLE-HS patients. Thus, the overexpression of the 
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postsynaptic 5-HT1A receptors can result in hyperpolarisation and suppress glutamate 
release, leading to inhibited neuronal activity and memory impairment (King et al., 2008).  
In terms of functionality of the 5-HT1A receptors, data generated by Cuellar-Herrera (et al., 
2014) using 8-OH-DPAT-stimulated [35S]-GTPγS binding assay on TLE-HS and PMC 
tissue homogenate, show a significant increase in 5-HT1A receptors functionality among 
TLE-HS compared to age match control hippocampi. The result of this study associated 
with significant diversity in the 5-HT1A functionality between TLE-HS patients. In order to 
minimise this inter-individual variability, the number of samples needs to be increased.  
Hence whilst an interesting finding that finds some support from previous studies using 
different research techniques, further laboratory studies are needed to better understand 
the upregulation of 5-HT1A receptors in the hippocampi of TLE-HS patients. This can be 
done using several methods, such as polyacrylamide gel electrophoresis (SDS-PAGE) 
Western blot in the presence of TLE-HS samples subjected to artificial post-mortem 
protocol to exclude the molecular effect of post-mortem delay upon protein expression. 
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Table 16. Studies on 5-HT1A receptors in TLE and MDD patients 
 
Result Type of patients 
Technique used for 





TLE PET ([11C]WAY-100635) Savic et al. (2004) 
High affinity 5-HT1A 
radioligand 
TLE PET ([11C]WAY-100635) Assem-Hilger et al. (2010) 
TLE PET ([18F]FCWAY) Toczek et al. (2003) 
TLE PET ([18F]FCWAY) Giovacchini et al. (2005) 
TLE PET ([18F]FCWAY) Theodore et al. (2007) 
TLE/MDD (AD naïve) PET ([11C]WAY-100635) Hasler et al. (2007) 





TLE/MDD (AD naïve) PET ([18F]MPPF) Lothe et al. (2008) 
Low affinity 5-HT1A 
radioligand 
MDD (AD naïve) PET ([11C]WAY-100635) Parsey et al. (2006) 














 5-HT2A receptors 
The second serotonergic G-protein was selected to study due to its important role in 
crucial brain functions such as memory development, was the expression of Gq/11 coupled 
excitatory 5-HT receptors, the 5-HT2A receptor. An immunohistochemistry study of 5-HT2A 
receptor immunoreactivity in the hippocampi of patients with TLE-HS revealed that, in 
comparison with post-mortem control hippocampi, this excitatory receptor was 
downregulated within what displayed the morphology of astrocytes within the 
hippocampus. This reduction in expression appeared to affect all expressed astrocytes 
across the entirety of the TLE-HS hippocampal subfields.  
This apparent downregulation of 5-HT2A receptors may have appeared as the result of a 
compensatory mechanism to decrease the activity of hyperactive neurons in the 
hippocampus by modulating glutamate release (Guiard and Di Giovanni, 2015). The 
downregulation might also result from continuous psychological stress, contributing to the 
reduction of 5-HT2A receptor density in hippocampal astrocytes (Egger, 2007, Dwivedi et 
al., 2005). Moreover, 5-HT2A receptor downregulation may manifest to improve the 
depressant-like behaviour associated with epilepsy (Sibille et al., 1997, Guiard and Di 
Giovanni, 2015). However, no data has been published regarding the cellular levels of 5-
HT2A receptor expression in the hippocampi of patients suffering from TLE-HS comorbid 
with depression or the levels of depression-free TLE-HS patients in comparison to post-
mortem control samples. A possible explanation for the reduction of 5-HT2A receptor 
density in TLE-HS patients is that this reduction may amount to a hippocampal 
physiological compensation strategy to improve memory impairment. However, the 
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downregulated 5-HT2A receptors might result from diffused immunoreactivity signals 
associated with an increase in the number of astrocyte processes. Considering the 
astrocytosis of TLE-HS samples, the overall 5-HT2A receptor expression level was higher 
than in post-mortem control samples.  In order to better evaluate the level of expression 
of 5-HT2A receptors in the astrocyte with respect to the increased number of cellular 
processes, a quantitative 5-HT2A immunofluorescence assay needs to be conducted using 
TLE-HS and PMC hippocampal sections. This study facilitates understanding the effect 
of TLE-HS on the 5-HT2A receptor expression in astrocytes and assess the possibility of 
5-HT2A receptors immunoreactivity signal diffusion through the increased number of 
astrocyte process. Such laboratory investigation helps to evaluate the possibility of 
targeting this receptor to control seizures among TLE-HS patients. 
In order to confirm the expression of 5-HT2A receptors in the astrocytes of human 
hippocampi, the immunoreactivity of GFAP proteins was used as a phenotypic marker in 
sections adjacent to those stained for 5-HT2A receptor immunoreactivity. The result 
displayed an approximate co-localisation of 5-HT2A receptors and GFAP proteins in 
hippocampal astrocytes. In agreement with previous data generated by Proper et al., 
(2000), GFAP immunoreactivity signals were significantly decreased in the CA4 cell 
bodies of patients with TLE-HS hippocampi, as compared with post-mortem controls. 
However, GFAP immunoreactivity signals were spread within the CA4 as a result of the 
significant increase in astrocyte processes (Proper et al., 2000). Moreover, in contrast to 
the astrocyte cell bodies of the CA4, the astrocyte cell bodies of the dentate gyrus 
molecular layer expressed higher immunoreactivity signals (Proper et al., 2000). 
158 
 
Interestingly, 5-HT2A receptor immunoreactivity signals followed patterns similar to those 
of GFAP expression in the dentate gyrus and CA4 of TLE-HS hippocampi. This finding 
parallels those observed in patients suffering from frontotemporal dementia, cerebral 
infarction, Alzheimer’s disease, Creutzfeldt-Jakob disease, hypertensive encephalopathy, 
and Huntington’s disease (Wu et al., 1999). 
Regarding the effect of TLE-HS upon expression of 5-HT2A receptor mRNA, the RT-qPCR 
result did not reveal any significant difference between diseased and control samples. The 
discrepancy between protein and mRNA expression may be a result of the disease 
negatively affecting the level of expression of 5-HT2A mRNA, leading to a decrease in the 
levels of 5-HT2A mRNA per cell. As a result of astrocytosis associated with TLE-HS, the 
downregulation of 5-HT2A mRNA was difficult to detect without conducting single cell RT-
qPCR using an equal number of cells from TLE-HS and post-mortem control samples. 
Further laboratory investigation is required to confirm findings and to assess the potential 
of antagonising 5-HT2A receptors to control seizures in TLE-HS patients. This can be 
accomplished using 5-HT2A receptor autoradiography and SDS-PAGE western blot to 
confirm the effect of TLE-HS on the expression of 5-HT2A receptors in patients. Moreover, 
in order to evaluate the level of expression of 5-HT2A receptors in the astrocyte with 
respect to the increased number of cellular processes, a quantitative 5-HT2A 
immunofluorescence assay need to be conducted using TLE-HS and PMC hippocampal 
sections. This study facilitates understanding the effect of TLE-HS on the 5-HT2A receptor 
expression in astrocytes and assess the possibility of 5-HT2A receptors immunoreactivity 
signal diffusion through the increased number of astrocyte process. Such laboratory 
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investigation helps to evaluate the possibility of targeting this receptor to control seizures 
among TLE-HS patients. Additionally, such methods can be used to study the effect of 5-
HT2A antagonists on the electrophysiological activity of hippocampi resected from TLE-
HS patients. The effect of 5-HT2A antagonists on attempts to elevate the chemo-induced 
(pentetrazol) seizure threshold was studied using juvenile C57BL/6 mice treated with 
ketanserin (selective 5-HT2A receptor antagonists) (Puzerey et al., 2014). Dual 
immunofluorescent staining of 5-HT2A receptors and GFAP proteins in hippocampi 
resected from TLE-HS patients need to be conducted and compared to post-mortem 
controls in order to assess the co-localisation and distribution patterns of these proteins 
in hippocampal astrocytes. In addition, study the possible pathways in which 5-
HT2A/GFAP proteins may intracellularly interact in order to understand the involvement of 
5-HT2A receptor in GFAP expression and astrocytes activation.
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 5-HT4 receptors 
Given the well-recognised important role of 5-HT4 receptors in the hippocampus, 
particularly associated with memory processes, and the evident colocalisation of 5-HT4 
receptors with inhibitory 5-HT1A receptors in hippocampal neurones (Roychowdhury, et 
al., 1994), the protein expression of the excitatory 5-HT4 receptors among TLE-HS was 
selected to be the next GPCR assessed in this study in comparison to post-mortem control 
samples.  
The results revealed an overexpression of the 5-HT4 receptors in the dentate gyrus and 
CA2 of patients with TLE-HS. This upregulation of these excitatory 5-HT4 receptors, like 
the increase in excitatory 5-HT3 receptor expression identified in the present study, is 
consistent with an increase in the over neuronal activity within the hippocampi of patients 
with TLE-HS. This indicates that this upregulation of 5-HT4 receptors could also play an 
important role in neuronal hyper-excitability among patients with TLE-HS. Based on that 
premise, antagonising the 5-HT4 receptors in TLE-HS patients may also help in managing 
this type of neuronal disease. Unfortunately, there are no marketed 5-HT4 receptor 
antagonists that could be assessed in a similarly designed clinical trial detailed earlier for 
assessment of a 5-HT3 receptor antagonist. It may be relevant, however, that some 5-HT4 
receptor agonists are marketed to promote gastric motility (e.g. the selective agonists 
prucalopride, cisapride and tegaserod [although the latter two have been withdrawn due 
to cardiac side-effects], and the non-selective agonist, metoclopramide; Quigley, 2015). 
However, it would be interesting to mine clinical data of patients with TLE-HS that have 
received any of these drugs to determine if treatment altered the frequency of their 
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seizures or not. Whilst such a meta-analysis of clinical data was outside the scope of the 
present thesis, such a project is worthy of consideration.   
On the other hand, this overexpression of 5-HT4 receptors may manifest as a result of a 
compensatory mechanism to memory impairment that was clinically observed in some of 
the TLE-HS patients (Hermann et al., 1997). Surprisingly, according to Haahr et al. (2013), 
there is an inverted relationship between the 5-HT4 receptors’ binding activity in the 
hippocampus and episodic memory in young healthy volunteers using PET. In this study 
5-HT4 receptors’ binding potential was decrease during episodic memory examination 
task in young healthy volunteers using highly selective 5-HT4 ligand, [11C]SB207145, 
(Haahr, et al., 2013).  
Furthermore, using the same 5-HT4 receptor ligand ([11C]SB207145) in a PET study of 
the level of expression of 5-HT4 receptors in healthy human volunteers and the level of 5-
HT tone, the results showed that increased synaptic 5-HT levels in the human brain are 
associated with a reduction in 5-HT4 binding activity (Haahr et al., 2014). As a result of 
the insensitivity of [11C]SB207145 radioactive ligand to the endogenous level of serotonin 
in the neuronal synapses (Marner et al., 2010), the possibility of pharmacological 
competition between endogenous serotonin and [11C]SB207145 binding activity is low. 
Accordingly, the result of this PET study may reflect a reduction in the 5-HT4 receptors’ 
expression after chronic treatment with selective serotonin reuptake inhibitors (SSRIs) for 
three weeks, which can cause a chronic increase in the synaptic concentration of 5-HT in 
the brain (Haahr et al., 2014). Therefore, the overexpression of 5-HT4 receptors in the 
hippocampus may result from a reduction in the synaptic concentration of 5-HT. This 
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hypothesis could be investigated further by measuring the 5-HT concentration in the 
hippocampi of patients undergoing surgical resection by in vivo microdialysis. 
Moreover, the 5-HT4 receptor upregulation in TLE-HS patients could be consequences of 
serotonergic neurons denervation that present in the form of neuronal cell loss 
phenomena in TLE-HS hippocampi. According to Compan et al., (1996), the 5-HT4 
receptor was upregulated in rat hippocampus (especially CA2) after exposed the animal 
to chemo-induced neuronal cell lesion using 5,7-dihydroxytryptamine injected into rat 
raphe nuclei. 
To the best of our knowledge, there is no available data about the expression or binding 
activity of 5-HT4 receptors in TLE-HS patients. Therefore, in order to confirm these results, 
further laboratory and clinical investigations using SDS-PAGE Western blot using 
selective anti-human 5-HT4 receptors antibody (to our knowledge, it is not available up to 
present time), and PET need to be conducted to compare with age-matched controls. This 
should be done to understand the role of these excitatory receptors in TLE-HS disease. 
Moreover, organotypic electrophysiological studies need to be conducted to examine the 
effect of antagonising these overexpressed excitatory receptors on the epileptic activity of 
the surgically resected epileptic hippocampi.     
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 5-HT7 receptors 
Studies of 5-HT7 receptors were conducted to understand the effect of TLE-HS disease 
on the expression levels of another Gs-coupled excitatory 5-HT receptors and to 
investigate the possibility of targeting those receptors to control seizures in TLE-HS 
patients as a number of 5-HT7 receptor antagonists are already available in the clinic e.g. 
the anti-psychotic agent, risperidone. In the present study, however, no consistent 
immunoreactivity signals were generated using the antibody available to label the 5-HT7 
receptor (Table 6), which prevents confident discussion of 5-HT7 receptor expression 
(Appendix 1). Since the 5-HT7 receptor remains a logical target to investigate, it is 
suggested that this receptor should be investigated using alternate anti-human 5-HT7 







4.2.C. Orphan G-protein, GPR61 
In addition to the serotonergic receptors, some interesting non-serotonergic proteins were 
selected to be assessed in the present study due to the opportune availability of useful 
antibodies in the Barnes laboratory. These studies also showed whether there was impact 
of TLE-HS upon other receptor systems. One of the proteins investigated was the orphan 
G-protein (GPR61). Relevance to study this receptor also arises due to its homologous 
genetic sequence and inclusion of biogenic amine receptors—specifically, 5-HT6 
receptors (Toyooka et al., 2009).  Also considered was the expression of mRNA within 
the CNS, particularly in the hippocampus, caudate, putamen (Cikos et al., 2001, Lee et 
al., 2001) and thalamus of the human brain (Lee et al., 2001). My study aimed to evaluate 
the level of expression of GPR61 protein in the human hippocampal subfield and to 
examine the level of expression of this protein in the pathogenesis of TLE-HS. Results of 
protein immunoreactivity revealed for the first time that GPR61 is widely expressed in 
human hippocampal subfields, to varying degrees. Thus, GPR61 immunoreactivity was 
strongly detected in CA1, CA2, and CA3, with more moderate signals detected in CA4 
and DG. The expression of the GPR61 protein in these areas may reflect its crucial role 
in higher brain functions (such as cognition, learning, and memory). The small 
immunoreactive blots appearing in the neuronal cell membrane may indicate that GPR61 
proteins present in a small vesicle or bind with other proteins in the cell membrane. 
However, there is no published data regarding the localisation of GPR61 protein in human 
hippocampal subfields or neuronal cells. 
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Regarding the impact of TLE-HS on GPR61 protein expression, it is clear that the disease 
has a pathological impact on the expression of the orphan G-protein in human 
hippocampal subfields. These effects include a moderate increase in the protein 
immunoreactivity in the granular cells of the dentate gyrus and the survival neurons of the 
CA3; moreover, a slight increase in the survival neurons of CA1 and preserved neurons 
of CA2 was shown. This finding may indicate the overexpression of GPR61 protein 
receptor partners—which, until the writing of this project, was scientifically undiscovered.  
Conversely, the level of GPR61 mRNA expression did not reveal any significant difference 
between TLE-HS and post-mortem control samples. This might be due either to TLE-HS’s 
lack of negative impact on GPR61 mRNA, or due to neurodegeneration phenomena of 
TLE-HS in hippocampal neurons that masks differences in the level of expression of 
mRNA compared to protein.  
Numerous laboratory studies conducted by multiple scientists aim to understand 
physiological functions, uncover downstream cellular mechanism pathways, reveal 
receptor partners, and discover a highly selective ligand to activate the orphan G-protein. 
To confirm results of protein expression in normal and TLE-HS human hippocampi, further 
laboratory investigations of resected human hippocampal samples should be conducted 
by for instance using SDS-PAGE western blot to evaluate the level of expression of 
GPR61 in each hippocampal comparison. Moreover, it would be very revealing to perform 
RT-qPCR evaluations using resected hippocampal subfields or even more revealing 
single cell RT-qPCR samples to relatively quantify the level of GPR61 mRNA changes to 
diseased samples, as compared with post-mortem control samples. To determine the 
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normal expression of GPR61 mRNA in human hippocampus subfields, in situ 
hybridisation must be used. Additionally, the impact of GPR61 proteins on higher brain 
functions should be investigated using GPR61 knockout mice. 
To assess the observation that GPR61 protein positive neuronal inclusion bodies were 
detected in one TLE-HS patient, neuropathological consultation was obtained from two 
consultant neuropathologists; Dr. Martyn Carey and Dr. Santhosh Nagaraju of Queen 
Elizabeth Hospital, Birmingham, United Kingdom. The consultants did not recognise these 
neuronal inclusion bodies in this type of neurological disease. Based on the relevant 
literature, neuronal inclusion bodies can be histopathologically observed in certain 
neurodegenerative diseases, such as frontotemporal dementia, where the inclusion 
bodies are ubiquitin positive (Forno et al., 2002, Mochizuki et al., 2004). The medical 
history of this patient did not reveal any neurological or psychological disease other than 
TLE-HS. Therefore, further laboratory and clinical investigations must be conducted to 





4.2.D. Purinergic ion channel, P2x7 receptors 
The other non-serotonergic receptor investigated in this study is the excitatory ionotropic 
non-selective purinergic cation channel, the P2x7 receptor. Similar to the other receptors 
studied in this project, expression of this receptor was studied using 
immunohistochemistry. Results revealed that the receptor was expressed at a relatively 
high level in the dentate gyrus and CA2 of hippocampi resected from TLE-HS patients, 
when compared to post-mortem control hippocampi. The upregulation of P2x7 in TLE-HS 
samples, particularly in the dentate gyrus, is comparable to findings by Doná et al., (2009) 
where P2x7 receptor immunoreactivity was studied in the pilocarpine-induced TLE-HS rat 
model during the chronic status epilepticus stage of the disease. This comparable finding 
between the species adds significance to the data and may suggest a role for this inotropic 
receptor in the excitotoxicity and neurodegeneration associated with TLE-HS, perhaps 
resulting in an increase in glutamate release and the facilitation of an influx of Ca2+ to the 
intracellular environment (Vianna et al., 2002). Using pilocarpine rat modals at the acute, 
latent, and chronic stages of status epilepticus (Doná et al., 2009), it was determined that 
the CA3 and CA1 are most affected. There is a lack of published data regarding the 
expression of P2x7 in human temporal lobe structures, with the exception of data 
generated by Jimenez-Pacheco et al. (2013), where the level of P2x7 expression was 
assessed in resected neocortex samples of TLE-HS patients using SDS-PAGE western 
blot. In this study, the level of expression of P2x7 was significantly higher among TLE-HS 
patients, consistent with the findings in the present study. 
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Similar to my previous discussion of the antagonism of the excitatory 5-HT3 receptor being 
potentially able to reduce seizure activity in patients with TLE-HS, antagonism of the P2x7 
receptor may also find therapeutic utility. Indeed, at the level of animal models, this 
hypothesis has already been examined using the P2x7 receptor antagonists, A-438079, 
in animal models of status epilepsy (Jimenez-Pacheco et al., 2013). In both studies, the 
P2x7 receptor antagonists displayed an anticonvulsive effect on seizure severity in the 
subject animals and was found to reduce the risk of neuronal death when using A-438079 
(Jimenez-Pacheco et al., 2013). No published data was found regarding the use of P2x7 
antagonists in clinical and experimental studies using TLE-HS patients or surgically 
resected TLE-HS hippocampi.  
Further laboratory investigation is warranted to confirm the upregulation of the excitatory 
P2x7 receptors among TLE-HS patients, which is consistent with the hyperexcitability of 
neuronal cells in this disease condition. Such studies could use SDS-PAGE western blot 
and receptor autoradiography in order to assess the level and location of protein 
expression. In addition, electrophysiological studies of P2x7 antagonists could be 
conducted to assess the anticonvulsive and neuroprotective properties of P2x7 receptor 
antagonists in patients with TLE-HS. These studies will facilitate introducing P2x7 as a 






4.2.E. Inconsistency between protein level of 5-HT1A, 5-HT 3A, 5-HT4 and P2x7 
receptors, and their mRNA in disease samples 
A clear and consistent finding in the present thesis was the discrepancy between the 
differences in protein expression or mRNA level of 5-HT3A, 5-HT1A, 5-HT4, P2x7 receptors 
and GPR61 protein when comparing tissues from patients with TLE-HS or ‘controls’. First, 
on the cellular protein expression level, the alteration in the protein expression level 
(especially 5-HT3A receptors) in TLE-HS hippocampal samples is due to the impact of 
disease on the protein level rather than the effect of post-mortem on the stability of protein 
and mRNA in hippocampal tissue. This finding is supported by the following observations 
in the expression of 5-HT3A receptors. A) data generated from hippocampal tissue lysate 
obtained from TLE-HS, PMC and TLE-HS, subjected to an artificial post-mortem delay 
protocol, samples on the 5-HT3A receptors expression compared to the constant level of 
housekeeping protein still reveals an upregulation in the receptor expression among TLE-
HS and those subjected to artificial post-mortem delay protocol. B) the expression pattern 
of 5-HT3A receptors in the dentate gyrus of TLE-HS resected hippocampi follows the 
histopathological changes (granular cells migration and sprouting of mossy fibres) that 
are associated with the disease.  
Second, on the level of tissue, the neurodegenerative effect of TLE-HS disease on the 
hippocampal neuronal cells viability. Thus the considerable reduction in the number of 
neurons in TLE-HS hippocampus compared to PMC sample may mask the changes in 
the level of mRNA expression and increase the difficulty in assessing this change among 
TLE-HS hippocampi in comparison to PMC samples. Further studies need to be 
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conducted to investigate this hypothesis. These studies can be performed by using 
different methods such as single cell RT-qPCR to quantify the level of mRNA in TLE-HS 
patients and controls using the same number of neurons from the same area or by using 
in situ hybridisation for localisation and semi-quantification of mRNA on a single cell basis. 
To exclude the post-mortem effect on the level of expression of mRNA, RT-qPCR was 
conducted to compare levels of expression in TLE-HS and post-mortem control samples 
to TLE-HS samples subjected to artificial post-mortem protocols. Due to the limited 
amount of total RNA, 5-HT3A receptor subunit genes were selected as a representative 
sample of target genes. Results indicated that the artificial post-mortem protocol affects 
the expression of the housekeeping genes (HPRT1 and ENO2), but not the target gene 
(5-HT3A), which was somewhat unexpected. Hence, study of a broader range of 
housekeeping genes may be warranted and hence allow a better understanding of the 
relative levels of receptor specific mRNA between tissues from patients with TLE-HS and 
relevant controls.  
Furthermore, technical issues associated with RT-qPCR (technical and biological 
differences, fluorescence-bleed) were assessed using 5-HT3A receptors, HPRT1, and 
ENO2 genes as a representative sample. Results did not indicate any significance 
(technical or biological) differences between disease and control samples. This result 
excludes the risk of pipetting error and the presence of significant biological differences 
between individuals in diseased and control groups. Conversely, some risk of 
fluorescence-bleed was observed when the RT-qPCR was conducted in duplex 
experimental protocols. However, this bleed did not significantly contribute to mask 
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differences between diseased and control samples. Therefore, the ideal method of 
detecting differences between TLE-HS and post-mortem controls involves the use of 
single-cell RT-qPCR to quantify the fold changes with respect to the number of neurons 
taken from diseased and post-mortem control samples. Additionally, in situ hybridisation 
techniques can be used to semi-quantify differences and uncover the anatomical 




4.2.F. General discussion 
The present study was conducted to obtain a better understanding of the impact of TLE-
HS on the expression level of multiple serotonergic and non-serotonergic receptors and 
proteins in an attempt to discover a novel target to reduce the seizures of patients with 
TLE-HS. The results of the present study demonstrate upregulations in the expression of 
the following proteins; 5-HT3A, 5-HT1A, 5-HT4 and P2x7 receptors in addition to the GPR61 
receptor in the hippocampus of patients with TLE-HS (see summary Figure 36). The 
confirmed overexpression of the excitatory 5-HT3 receptors in the hippocampus of 
patients with TLE-HS is consistence to the neuronal hyperexcitability. Therefore, we 
propose antagonizing this receptor with drugs that are already marketed may offer 
symtomatic relief for patients with TLE-HS and hence may improve their quality of life 
without the need for potentially debilitating neurosurgery. This suggest that this hypothesis 
is evaluated in a Phase II trial, which may forward evidence to expand the clinical 
indications for which 5-HT3 receptor antagonists provide benefit.  
In addition, the overexpression of inhibitory 5-HT1A receptors could be a compensatory 
mechanism to adapt the hyperexcitable neurons due to disease. Moreover, this increase 
in 5-HT1A receptors expression may play a role in the underline mechanism of memory 
defect that is clinically observed in some patients with TLE-HS. Regarding the excitatory 
5-HT4 and P2x7 receptors, the upregulation of these receptors could also play an 
important role in the underline mechanism of seizure activity in TLE=HS disease. The 
overexpression of 5-HT4 receptors could also be a compensatory mechanism for memory 
impairment in some patients with TLE-HS patients or as a result of the reduction in the 
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synaptic concentration of serotonin. Therefore, antagonizing this receptor may also help 
in seizure control and improve memory among TLE-HS patients. P2x7 overexpression 
may be involved in the neuronal excitotoxicity and neurodegeneration that is associated 
with the disease. Hence, antagonizing these excitatory receptors may introduce 5-HT4 
and P2x7 as additional novel targets to benefit patients with TLE-HS.  
Regarding the orphan G-protein (GPR61), this protein expresses a variable degree of 
protein upregulation among hippocampus of TLE-HS patients. The biological function of 
this protein is poorly understood. The present study also investigates the impact of 
disease on 5-HT2A receptors expression, however, no clear results were obtained.  
In contrast to the protein expression of the receptors understudy, the mRNA level did not 
reveal any significant differences between disease and control samples. This 
inconsistency in the result could be due to the neurodegenerative effect of the disease in 
hippocampus neurons. 
In summary, the main finding from this project is the forwarding of a scientific rationale 
based on experimental evidence that 5-HT3 receptor antagonists may offer a novel 
pharmacological strategy to reduce the seizures of patients with TLE-HS and hence 
improve their quality of life. Although with less evidence that with respect to the 5-HT3 
receptor antagonists, the present study also forwards some support to investigate the 
potential therapeutic actions of antagonists of 5-HT4 receptors and P2x7 receptors to 





Figure 36. Schematic representation of the changes in various receptors expressed 
in the hippocampus of patients with TLE-HS compared with control donors. 
The naming of a receptor in red indicates a higher level of expression in TLE-HS 
















Temporal lobe epilepsy with hippocampal sclerosis is the most common type of epilepsy 
affecting adults. This disease is characterised by recurrent partial seizures affecting the 
medial part of the temporal lobe, in particular the hippocampus. Seizure in this 
neurological disorder can be controlled using various types of AEDs in the early stages of 
the disease; however, these medications are failing to control seizures during the 
advanced stages of TLE-HS. As a result of this pharmaco-resistance, surgical intervention 
(hippocampectomy or amygdalohippocampectomy) is the last chance to control seizures 
in these patients. In order to control seizures to improve TLE-HS patients' quality of life 
and to avoid the negative effects of surgical intervention on patients’ memory and 
cognition, the identification of novel targets is crucial in controlling seizures and 
decreasing the risk of surgical intervention. Therefore, this study was conducted to assess 
the possible involvement of select serotonergic receptors (5-HT1A, 5-HT2A, 5-HT3A, 5-HT4 
and 5-HT7) and other selected interesting targets (GPR61 protein and P2x7 receptors) in 
order to identify a potential novel targets to evaluate drug action. The results of these 
screening present various alteration in targets expression in hippocampus of TLE-HS 
patients. These results propose possible novel target (the priority from the presence study 
is to investigate antagonising 5-HT3 receptors) that could be used alone or as an 
adjunctive therapy with AEDs to control seizures and potentially also improve memory 
deficit in TLE-HS patients. It may be precedent to perform further laboratory investigation 
to confirm those finding and to physiologically assess targeting these receptors in TLE-















6.1.   Appendix A – 5-HT7 receptors immunoreactivity. 
 
Figure 37. Intermittent and non-specific immunoreactivity signals of 5-HT7 receptors antibody.  
A) Dentate gyrus and CA4 of two different PMC samples, Top = PMC (1), Bottom = PMC (2). B) Dentate gyrus and 
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